##analysisDate=2017-05-10-14-03-37000
##analyzedBy=RingStudy Site F
##exportDate=2017-11-08-10-48-24000
##analysisName=Site F-081-Sample 2_F
##workflowName=Oncomine Comprehensive v3 - w2.1 - DNA and Fusions - Single Sample
##sampleNames=Site F-081-Sample 2-F_v1:Site F-081-Sample 2-F_RNA_v1
##reference=hg19
##variantGroup=DEFAULT
##filterChain=Site D_NoRef
##searchText=
##chromosome=All
##totalVariantCount=2493
##filterInCount=114
##filteredOutCount=2379
##hiddenVariantCount=0
Locus	Genotype	Ref	Type	No Call Reason	Genes	Location	Length	Oncomine Variant Class	Oncomine Gene Class	Copy Number	CytoBand	Info	Variant ID	Variant Name	% Frequency	Amino Acid Change	Read Counts	Coverage	Allele Ratio	CNV Confidence	Detection	3'/5' Imbalance	COSMIC/NCBI	Read Counts Per Million	Strand	Exon	Transcript	Coding	Variant Effect	PhyloP	SIFT	Grantham	PolyPhen	PFAM	dbSNP	DGV	MAF	EMAF	AMAF	GMAF	UCSC Common SNPs	Gene Ontology	DrugBank	ClinVar	p-value	Phred QUAL Score	Allele Coverage	CNV Precision	Ref+/Ref-/Var+/Var-	Homopolymer Length	Tiles
chr1:40363054	C/C	G	SNV		MYCL	exonic	1								100.00	p.Thr392Ser		1102	G=0.0, C=1.0		Present				-	3	NM_001033082.2	c.1175C>G	missense	1.32	1.0	58.0	0.0	Helix-loop-helix DNA-binding domain,Myc amino-terminal region	rs3134614		0.055 (ref)	0.1328	0.0252	0.0963	YES	DNA binding,nucleus,regulation of transcription, DNA-dependent,sequence-specific DNA binding transcription factor activity			0.00001	16727.0	G=0, C=1102		G=0/0, C=550/552	1	
chr1:65310489	T/C	T	SNV		JAK1	exonic	1								30.15	p.(=)		1625	T=0.6985, C=0.3015		Present				-	16	NM_002227.2	c.2199A>G	synonymous	-4.13				Protein kinase domain,Protein tyrosine kinase	rs2230588		0.352 (ref)	0.2323	0.418	0.3492	YES	ATP binding,cytokine-mediated signaling pathway,cytoplasm,cytoskeleton,cytosol,endomembrane system,growth hormone receptor binding,interferon-gamma-mediated signaling pathway,intracellular protein kinase cascade,intracellular signal transduction,membrane,non-membrane spanning protein tyrosine kinase activity,nucleotide binding,nucleus,protein binding,protein phosphorylation,protein tyrosine kinase activity,regulation of interferon-gamma-mediated signaling pathway,regulation of type I interferon-mediated signaling pathway,response to antibiotic,type I interferon-mediated signaling pathway	2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZH-IMIDAZ4,5-FISOQUINOLIN-7-ONE,3-{(3R,4R)-4-methyl-3-methyl(7H-pyrrolo2,3-dpyrimidin-4-yl)aminopiperidin-1-yl}-3-oxopropanenitrile		0.00001	3322.82	T=1135, C=490		T=520/615, C=217/273	1	
chr1:156846233	G/A	G	SNV		NTRK1	exonic	1								49.02	p.(=)		1075	G=0.5098, A=0.4902		Present				+	14	NM_002529.3	c.1674G>A	synonymous	0.77				Protein kinase domain,Protein tyrosine kinase	rs6334		0.213 (ref)	0.2194	0.1432	0.1936	YES	ATP binding,Ras protein signal transduction,activation of MAPKK activity,activation of adenylate cyclase activity,activation of phospholipase C activity,axonogenesis involved in innervation,cell differentiation,developmental programmed cell death,endosome,integral to plasma membrane,multicellular organismal development,negative regulation of cell proliferation,negative regulation of neuron apoptosis,nerve growth factor binding,nerve growth factor receptor activity,nerve growth factor receptor signaling pathway,nervous system development,neurotrophin binding,nucleotide binding,phosphatidylinositol-mediated signaling,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of NF-kappaB transcription factor activity,positive regulation of Ras GTPase activity,positive regulation of Ras protein signal transduction,positive regulation of angiogenesis,positive regulation of neuron projection development,positive regulation of programmed cell death,protein autophosphorylation,protein binding,protein homodimerization activity,protein phosphorylation,receptor activity,small GTPase mediated signal transduction,sympathetic nervous system development,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway	Amitriptyline,Imatinib		0.00001	4893.57	G=548, A=527		G=307/241, A=222/305	1	
chr1:204485637		G	GENE_EXPRESSION		MDM4								MDM4.E1E2				168				Present			1.9149e-10																						0.0					
chr1:204494724		G	GENE_EXPRESSION		MDM4								MDM4.E3E4				695				Present			7.9216e-10																						0.0					
chr2:29445458	G/T	G	SNV		ALK	exonic	1								54.59	p.(=)		1471	G=0.4541, T=0.5459		Present				-	21	NM_004304.4	c.3375C>A	synonymous	-1.83				MAM domain,Protein kinase domain,Protein tyrosine kinase	rs3795850		0.395 (ref)	0.2058	0.2519	0.2214	YES	ATP binding,NF-kappaB-inducing kinase activity,activation of MAPK activity,cell proliferation,integral to plasma membrane,neuron development,nucleotide binding,phosphorylation,plasma membrane,positive regulation of NF-kappaB transcription factor activity,protein autophosphorylation,receptor activity,regulation of apoptotic process,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	7961.75	G=668, T=803		G=321/347, T=421/382	1	
chr2:48030632	G/T	G	SNV		MSH6	exonic	1								43.93	p.(=)		1994	G=0.5607, T=0.4393		Present				+	5	NM_000179.2	c.3246G>T	synonymous	0.33				MutS domain I,MutS domain II,MutS domain III,MutS domain V,MutS family domain IV,PWWP domain	rs3136351		0.002	0.0053	0.0011	0.0039		ADP binding,ATP binding,ATP catabolic process,ATPase activity,DNA damage response, signal transduction resulting in induction of apoptosis,DNA repair,DNA-dependent ATPase activity,MutLalpha complex binding,MutSalpha complex,chromatin binding,damaged DNA binding,determination of adult lifespan,double-stranded DNA binding,four-way junction DNA binding,guanine/thymine mispair binding,induction of apoptosis by intracellular signals,isotype switching,magnesium ion binding,maintenance of DNA repeat elements,meiotic mismatch repair,mismatch repair,mismatched DNA binding,negative regulation of DNA recombination,nuclear chromatin,nuclear chromosome,nucleotide binding,nucleus,oxidized purine DNA binding,positive regulation of helicase activity,protein binding,protein homodimerization activity,reciprocal meiotic recombination,response to UV,single guanine insertion binding,single thymine insertion binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments		probable-non-pathogenic	0.00001	7601.67	G=1118, T=876		G=498/620, T=392/484	2	
chr3:37053568	A/G	A	SNV		MLH1	exonic	1								52.03	p.Ile219Val		1999	A=0.4797, G=0.5203		Present				+	8	NM_000249.3	c.655A>G	missense	2.21	0.17	29.0	0.018	DNA mismatch repair protein,Histidine kinase-	rs1799977		0.172	0.3202	0.0921	0.243	YES	ATP binding,ATP catabolic process,ATPase activity,DNA damage response, signal transduction resulting in induction of apoptosis,MutLalpha complex,MutLbeta complex,MutSalpha complex binding,cell cycle,cellular response to organic cyclic compound,chiasma,double-strand break repair via nonhomologous end joining,guanine/thymine mispair binding,isotype switching,male germ cell nucleus,male meiosis chromosome segregation,meiotic metaphase I plate congression,mismatch repair,mismatched DNA binding,negative regulation of mitotic recombination,nuclear-transcribed mRNA poly(A) tail shortening,nucleus,oogenesis,pachytene,protein binding,reciprocal meiotic recombination,resolution of meiotic recombination intermediates,response to drug,response to hypoxia,response to toxin,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,spermatogenesis,spindle midzone assembly involved in meiosis,synaptonemal complex		non-pathogenic,probable-non-pathogenic	0.00001	10015.1	A=959, G=1040		A=483/476, G=546/494	1	
chr3:47125385	A/A	G	SNV		SETD2	exonic	1								100.00	p.Pro1962Leu		1992	G=0.0, A=1.0		Present				-	12	NM_014159.6	c.5885C>T	missense	0.33	0.06	98.0	0.0	SET domain,WW domain	rs4082155		0.496 (ref)	0.4338	0.2862	0.4713	YES	DNA binding,chromatin modification,chromosome,histone H3-K36 methylation,histone-lysine N-methyltransferase activity,methyltransferase activity,nucleus,oxidoreductase activity,peptidyl-lysine trimethylation,protein binding,regulation of transcription, DNA-dependent,transferase activity,transition metal ion binding			0.00001	30240.5	G=0, A=1992		G=0/0, A=1017/975	3	
chr3:47162661	G/G	A	SNV		SETD2	exonic	1								100.00	p.(=)		1978	A=0.0, G=1.0		Present				-	3	NM_014159.6	c.3465T>C	synonymous	-0.59				SET domain,WW domain	rs6767907		0.316 (ref)	0.4088	0.2506	0.3552	YES	DNA binding,chromatin modification,chromosome,histone H3-K36 methylation,histone-lysine N-methyltransferase activity,methyltransferase activity,nucleus,oxidoreductase activity,peptidyl-lysine trimethylation,protein binding,regulation of transcription, DNA-dependent,transferase activity,transition metal ion binding			0.00001	30139.2	A=0, G=1978		A=0/0, G=980/998	1	
chr3:142178144	C/T	C	SNV		ATR	exonic	1								50.88	p.Arg2425Gln		1999	C=0.4912, T=0.5088		Present				-	43	NM_001184.3	c.7274G>A	missense	-2.53	0.5	43.0	0.0	FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase,UME (NUC010) domain	rs2229032		0.12 (ref)	0.1578	0.0881	0.1342	YES	ATP binding,DNA binding,DNA damage checkpoint,DNA repair,DNA replication,MutLalpha complex binding,MutSalpha complex binding,PML body,XY body,cell cycle,cell cycle checkpoint,cellular response to UV,cellular response to gamma radiation,multicellular organismal development,negative regulation of DNA replication,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,protein autophosphorylation,protein binding,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of protein binding,replicative senescence,response to DNA damage stimulus			0.00001	9653.32	C=982, T=1017		C=488/494, T=511/506	1	
chr3:142222284	A/G	A	SNV		ATR	exonic	1								46.93	p.(=)		1581	A=0.5307, G=0.4693		Present				-	30	NM_001184.3	c.5208T>C	synonymous	0.03				FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase,UME (NUC010) domain	rs2227931		0.352 (ref)	0.4189	0.2145	0.3496	YES	ATP binding,DNA binding,DNA damage checkpoint,DNA repair,DNA replication,MutLalpha complex binding,MutSalpha complex binding,PML body,XY body,cell cycle,cell cycle checkpoint,cellular response to UV,cellular response to gamma radiation,multicellular organismal development,negative regulation of DNA replication,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,protein autophosphorylation,protein binding,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of protein binding,replicative senescence,response to DNA damage stimulus			0.00001	6688.53	A=839, G=742		A=370/469, G=345/397	1	
chr3:142277536	A/G	A	SNV		ATR	exonic	1								49.27	p.(=)		1999	A=0.5073, G=0.4927		Present				-	8	NM_001184.3	c.1815T>C	synonymous	0.12				FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase,UME (NUC010) domain	rs2227929		0.349 (ref)	0.414	0.2127	0.3458	YES	ATP binding,DNA binding,DNA damage checkpoint,DNA repair,DNA replication,MutLalpha complex binding,MutSalpha complex binding,PML body,XY body,cell cycle,cell cycle checkpoint,cellular response to UV,cellular response to gamma radiation,multicellular organismal development,negative regulation of DNA replication,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,protein autophosphorylation,protein binding,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of protein binding,replicative senescence,response to DNA damage stimulus			0.00001	9163.5	A=1014, G=985		A=539/475, G=581/404	1	
chr3:142277575	T/T	A	SNV		ATR	exonic	1								100.00	p.(=)		2000	A=0.0, T=1.0		Present				-	8	NM_001184.3	c.1776T>A	synonymous	-0.09				FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase,UME (NUC010) domain	rs2227930		0.382 (ref)	0.405	0.2043	0.337	YES	ATP binding,DNA binding,DNA damage checkpoint,DNA repair,DNA replication,MutLalpha complex binding,MutSalpha complex binding,PML body,XY body,cell cycle,cell cycle checkpoint,cellular response to UV,cellular response to gamma radiation,multicellular organismal development,negative regulation of DNA replication,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,protein autophosphorylation,protein binding,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of protein binding,replicative senescence,response to DNA damage stimulus			0.00001	30468.6	A=0, T=2000		A=0/0, T=1061/939	1	
chr3:142281612	G/G	A	SNV		ATR	exonic	1								100.00	p.Met211Thr		1989	A=0.0, G=1.0		Present				-	4	NM_001184.3	c.632T>C	missense	0.55	1.0	81.0	0.0	FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase,UME (NUC010) domain	rs2227928		0.383 (ref)	0.4045	0.2072	0.3377	YES	ATP binding,DNA binding,DNA damage checkpoint,DNA repair,DNA replication,MutLalpha complex binding,MutSalpha complex binding,PML body,XY body,cell cycle,cell cycle checkpoint,cellular response to UV,cellular response to gamma radiation,multicellular organismal development,negative regulation of DNA replication,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,protein autophosphorylation,protein binding,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of protein binding,replicative senescence,response to DNA damage stimulus			0.00001	30164.9	A=0, G=1989		A=0/0, G=988/1001	1	
chr4:1807894	A/A	G	SNV		FGFR3	exonic	1								100.00	p.(=)		1109	G=0.0, A=1.0		Present				+	14	NM_000142.4	c.1953G>A	synonymous	0.05				Immunoglobulin I-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs7688609		0.042 (ref)	8.0E-4	0.131	0.0449	YES	ATP binding,JAK-STAT cascade,MAPKKK cascade,bone maturation,bone morphogenesis,chondrocyte differentiation,chondrocyte proliferation,cytoplasmic membrane-bounded vesicle,endochondral bone growth,endochondral ossification,endoplasmic reticulum,fibroblast growth factor binding,fibroblast growth factor receptor signaling pathway,fibroblast growth factor-activated receptor activity,focal adhesion,insulin receptor signaling pathway,integral to plasma membrane,negative regulation of developmental growth,nucleotide binding,peptidyl-tyrosine phosphorylation,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of MAPKKK cascade,positive regulation of cell proliferation,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phospholipase activity,positive regulation of tyrosine phosphorylation of Stat1 protein,positive regulation of tyrosine phosphorylation of Stat3 protein,protein autophosphorylation,protein binding,protein tyrosine kinase activity,receptor activity,regulation of apoptotic process,skeletal system development	Palifermin,Pazopanib		0.00001	16859.3	G=0, A=1109		G=0/0, A=571/538	1	
chr4:55141051	GCCCGGATGGACATGA/GCCCGGATGGACATGA	GCCCAGATGGACATGA	SNV		PDGFRA	exonic	1					HS	COSM12418		G=0.00, GCCCGGATGGACATGA=100.00	p.(=)		1971	GCCCAGATGGACATGA=0.0, G=0.0, GCCCGGATGGACATGA=1.0		Present				+	12	NM_006206.4	c.1701A>G	synonymous	2.79,2.74,2.74,2.74,-5.31,2.74,2.21,0.99,2.74,2.74,0.41,2.64,2.31,-0.28,1.57,2.31				Immunoglobulin I-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs121913270,rs121913271,rs1873778,rs201503614		0.037				YES	ATP binding,Leydig cell differentiation,adrenal gland development,cardiac myofibril assembly,cell activation,cell chemotaxis,cellular response to amino acid stimulus,cytoplasm,elevation of cytosolic calcium ion concentration,embryonic cranial skeleton morphogenesis,embryonic digestive tract morphogenesis,embryonic skeletal system morphogenesis,estrogen metabolic process,extracellular matrix organization,face morphogenesis,female gonad development,gliogenesis,growth factor binding,in utero embryonic development,inner ear development,integral to plasma membrane,intrinsic to plasma membrane,lung development,luteinization,male genitalia development,metanephric glomerular capillary formation,multicellular organismal development,negative regulation of platelet activation,nucleotide binding,nucleus,odontogenesis of dentin-containing tooth,palate development,peptidyl-tyrosine phosphorylation,phosphatidylinositol 3-kinase binding,phosphatidylinositol-mediated signaling,plasma membrane,platelet aggregation,platelet-derived growth factor alpha-receptor activity,platelet-derived growth factor binding,platelet-derived growth factor receptor binding,platelet-derived growth factor receptor signaling pathway,platelet-derived growth factor receptor-alpha signaling pathway,positive regulation of DNA replication,positive regulation of ERK1 and ERK2 cascade,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of fibroblast proliferation,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of phospholipase C activity,protein autophosphorylation,protein homodimerization activity,protein tyrosine kinase activity,receptor activity,regulation of actin cytoskeleton reorganization,regulation of chemotaxis,regulation of mesenchymal stem cell differentiation,response to cytokine stimulus,response to estradiol stimulus,response to hormone stimulus,response to hyperoxia,response to inorganic substance,retina vasculature development in camera-type eye,signal transduction involved in regulation of gene expression,transmembrane receptor protein tyrosine kinase activity,vascular endothelial growth factor receptor signaling pathway,vascular endothelial growth factor-activated receptor activity,wound healing	Becaplermin,Imatinib,Pazopanib,Sunitinib		0.00001	28612.4	GCCCAGATGGACATGA=0, G=0, GCCCGGATGGACATGA=1971		GCCCAGATGGACATGA=0/0, G=0/0, GCCCGGATGGACATGA=937/1034	3,1	
chr4:55593464	A/C	A	SNV		KIT	exonic	1	Hotspot	Gain-of-function						60.81	p.Met541Leu		1850	A=0.3919, C=0.6081		Present				+	10	NM_000222.2	c.1621A>C	missense	0.46	0.39	15.0	0.009	Immunoglobulin I-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs3822214		0.064	0.1119	0.0636	0.0955	YES	ATP binding,activation of MAPK activity,cytokine binding,cytokine-mediated signaling pathway,cytoplasm,external side of plasma membrane,extracellular space,germ cell programmed cell death,glycosphingolipid metabolic process,hemopoiesis,integral to membrane,intracellular protein kinase cascade,lymphoid progenitor cell differentiation,male gonad development,mast cell differentiation,mast cell proliferation,melanocyte differentiation,metal ion binding,myeloid progenitor cell differentiation,negative regulation of programmed cell death,nucleotide binding,nucleus,peptidyl-tyrosine phosphorylation,plasma membrane,positive regulation of JAK-STAT cascade,positive regulation of MAPKKK cascade,positive regulation of gene expression,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of phospholipase C activity,positive regulation of sequence-specific DNA binding transcription factor activity,positive regulation of tyrosine phosphorylation of Stat1 protein,positive regulation of tyrosine phosphorylation of Stat3 protein,positive regulation of tyrosine phosphorylation of Stat5 protein,protein autophosphorylation,protein binding,protein homodimerization activity,protein tyrosine kinase activity,receptor activity,receptor signaling protein tyrosine kinase activity,regulation of cell proliferation,regulation of developmental pigmentation,response to radiation,signal transduction,spermatid development,spermatogenesis,stem cell factor receptor activity,stem cell maintenance,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway	Adenosine-5'-Diphosphate,Dasatinib,Imatinib,Nilotinib,Pazopanib,Phosphonotyrosine,Sorafenib,Sunitinib		0.00001	11850.3	A=725, C=1125		A=405/320, C=586/539	1	
chr4:55602765	G/C	G	SNV		KIT	exonic	1								58.51	p.(=)		1998	G=0.4149, C=0.5851		Present				+	18	NM_000222.2	c.2586G>C	synonymous	-0.49				Immunoglobulin I-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs3733542		0.144 (ref)	0.1253	0.3252	0.1931	YES	ATP binding,activation of MAPK activity,cytokine binding,cytokine-mediated signaling pathway,cytoplasm,external side of plasma membrane,extracellular space,germ cell programmed cell death,glycosphingolipid metabolic process,hemopoiesis,integral to membrane,intracellular protein kinase cascade,lymphoid progenitor cell differentiation,male gonad development,mast cell differentiation,mast cell proliferation,melanocyte differentiation,metal ion binding,myeloid progenitor cell differentiation,negative regulation of programmed cell death,nucleotide binding,nucleus,peptidyl-tyrosine phosphorylation,plasma membrane,positive regulation of JAK-STAT cascade,positive regulation of MAPKKK cascade,positive regulation of gene expression,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of phospholipase C activity,positive regulation of sequence-specific DNA binding transcription factor activity,positive regulation of tyrosine phosphorylation of Stat1 protein,positive regulation of tyrosine phosphorylation of Stat3 protein,positive regulation of tyrosine phosphorylation of Stat5 protein,protein autophosphorylation,protein binding,protein homodimerization activity,protein tyrosine kinase activity,receptor activity,receptor signaling protein tyrosine kinase activity,regulation of cell proliferation,regulation of developmental pigmentation,response to radiation,signal transduction,spermatid development,spermatogenesis,stem cell factor receptor activity,stem cell maintenance,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway	Adenosine-5'-Diphosphate,Dasatinib,Imatinib,Nilotinib,Pazopanib,Phosphonotyrosine,Sorafenib,Sunitinib		0.00001	12089.4	G=829, C=1169		G=421/408, C=577/592	1	
chr5:1294086	C/T	C	SNV		TERT	exonic	1								55.23	p.(=)		1997	C=0.4477, T=0.5523		Present				-	2	NM_198253.2	c.915G>A	synonymous	-1.35					rs2736098		0.213 (ref)	0.2597	0.1051	0.2075	YES	DNA binding,DNA strand elongation,PML body,anti-apoptosis,chromosome,chromosome, telomeric region,cytoplasm,metal ion binding,nuclear telomere cap complex,nucleolus,nucleoplasm,nucleotidyltransferase activity,nucleus,protein binding,protein homodimerization activity,replicative senescence,telomerase activity,telomerase holoenzyme complex,telomere formation via telomerase,telomere maintenance,telomere maintenance via telomerase,telomeric DNA binding,telomeric RNA binding,telomeric template RNA reverse transcriptase activity,transferase activity		non-pathogenic	0.00001	11015.1	C=894, T=1103		C=450/444, T=528/575	3	
chr5:38955796	G/A	G	SNV		RICTOR	exonic	1								55.43	p.Ser837Phe		1999	G=0.4457, A=0.5543		Present				-	26	NM_152756.4	c.2510C>T	missense	1.26	0.7	155.0	0.002		rs2043112		0.392 (ref)	0.401	0.2853	0.3618	YES	T cell costimulation,TORC2 complex,actin cytoskeleton reorganization,cytosol,embryo development,fibroblast growth factor receptor signaling pathway,nerve growth factor receptor signaling pathway,phosphatidylinositol-mediated signaling,positive regulation of TOR signaling cascade,positive regulation of actin filament polymerization,positive regulation of peptidyl-tyrosine phosphorylation,protein binding,regulation of Rac GTPase activity,regulation of actin cytoskeleton organization,regulation of protein kinase B signaling cascade,ribosome binding			0.00001	11088.5	G=891, A=1108		G=443/448, A=544/564	2	
chr5:67522722	C/T	C	SNV		PIK3R1	exonic	1								56.03	p.(=)		1999	C=0.4397, T=0.5603		Present				+	2	NM_181523.2	c.219C>T	synonymous	-2.42				RhoGAP domain,SH2 domain,SH3 domain	rs706713		0.442 (ref)	0.234	0.4092	0.2933	YES	1-phosphatidylinositol binding,1-phosphatidylinositol-4-phosphate 3-kinase, class IA complex,ErbB-3 class receptor binding,T cell costimulation,T cell receptor signaling pathway,blood coagulation,cytosol,epidermal growth factor receptor signaling pathway,fibroblast growth factor receptor signaling pathway,growth hormone receptor signaling pathway,insulin binding,insulin receptor binding,insulin receptor signaling pathway,insulin receptor substrate binding,insulin-like growth factor receptor binding,insulin-like growth factor receptor signaling pathway,interspecies interaction between organisms,intracellular,leukocyte migration,nerve growth factor receptor signaling pathway,neurotrophin TRKA receptor binding,phosphatidylinositol 3-kinase cascade,phosphatidylinositol 3-kinase regulator activity,phosphatidylinositol phosphorylation,phosphatidylinositol-4,5-bisphosphate 3-kinase activity,phosphatidylinositol-mediated signaling,platelet activation,positive regulation of establishment of protein localization in plasma membrane,positive regulation of glucose import,protein binding,protein phosphatase binding,signal transduction	(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-(METHYLOXY)METHYL-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO4,3,2-DEINDENO4,5-H2BENZOPYRAN-11-YL ACETATE,Isoproterenol		0.00001	11282.2	C=879, T=1120		C=421/458, T=556/564	1	
chr5:67588148	G/A	G	SNV		PIK3R1	exonic	1								44.77	p.Met326Ile		1999	G=0.5523, A=0.4477		Present				+	8	NM_181523.2	c.978G>A	missense	1.5	0.42	10.0	0.0	RhoGAP domain,SH2 domain,SH3 domain	rs3730089		0.218 (ref)	0.1645	0.3822	0.2383	YES	1-phosphatidylinositol binding,1-phosphatidylinositol-4-phosphate 3-kinase, class IA complex,ErbB-3 class receptor binding,T cell costimulation,T cell receptor signaling pathway,blood coagulation,cytosol,epidermal growth factor receptor signaling pathway,fibroblast growth factor receptor signaling pathway,growth hormone receptor signaling pathway,insulin binding,insulin receptor binding,insulin receptor signaling pathway,insulin receptor substrate binding,insulin-like growth factor receptor binding,insulin-like growth factor receptor signaling pathway,interspecies interaction between organisms,intracellular,leukocyte migration,nerve growth factor receptor signaling pathway,neurotrophin TRKA receptor binding,phosphatidylinositol 3-kinase cascade,phosphatidylinositol 3-kinase regulator activity,phosphatidylinositol phosphorylation,phosphatidylinositol-4,5-bisphosphate 3-kinase activity,phosphatidylinositol-mediated signaling,platelet activation,positive regulation of establishment of protein localization in plasma membrane,positive regulation of glucose import,protein binding,protein phosphatase binding,signal transduction	(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-(METHYLOXY)METHYL-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO4,3,2-DEINDENO4,5-H2BENZOPYRAN-11-YL ACETATE,Isoproterenol		0.00001	7860.49	G=1104, A=895		G=501/603, A=434/461	1	
chr5:149504348	C/T	C	SNV		PDGFRB	exonic	1								56.86	p.(=)		1333	C=0.4314, T=0.5686		Present				-	13	NM_002609.3	c.1854G>A	synonymous	-1.02				Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs56072663		0.012 (ref)	0.0377	0.0061	0.027	YES	ATP binding,adrenal gland development,aorta morphogenesis,apical plasma membrane,cardiac myofibril assembly,cell chemotaxis,cell migration,cell migration involved in coronary angiogenesis,cell migration involved in vasculogenesis,cytoplasm,cytoplasmic membrane-bounded vesicle,growth factor binding,in utero embryonic development,integral to plasma membrane,intrinsic to plasma membrane,kidney development,lysosomal lumen,membrane,metanephric glomerular capillary formation,metanephric glomerular mesangial cell proliferation involved in metanephros development,multicellular organismal development,nitrogen compound metabolic process,nucleotide binding,nucleus,peptidyl-tyrosine phosphorylation,phosphatidylinositol metabolic process,phosphatidylinositol-mediated signaling,plasma membrane,platelet activating factor receptor activity,platelet-derived growth factor beta-receptor activity,platelet-derived growth factor binding,platelet-derived growth factor receptor binding,platelet-derived growth factor receptor signaling pathway,platelet-derived growth factor receptor-beta signaling pathway,platelet-derived growth factor-activated receptor activity,positive regulation of DNA biosynthetic process,positive regulation of ERK1 and ERK2 cascade,positive regulation of MAP kinase activity,positive regulation of calcium ion import,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of chemotaxis,positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway,positive regulation of mitosis,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of phospholipase C activity,positive regulation of phosphoprotein phosphatase activity,positive regulation of reactive oxygen species metabolic process,positive regulation of smooth muscle cell migration,positive regulation of smooth muscle cell proliferation,protein autophosphorylation,protein binding,protein tyrosine kinase activity,receptor activity,receptor binding,regulation of actin cytoskeleton organization,regulation of peptidyl-tyrosine phosphorylation,retina vasculature development in camera-type eye,signal transducer activity,signal transduction,skeletal system morphogenesis,smooth muscle cell chemotaxis,smooth muscle tissue development,tissue homeostasis,vascular endothelial growth factor-activated receptor activity	Becaplermin,Dasatinib,Imatinib,Pazopanib,Sorafenib,Sunitinib		0.00001	7666.0	C=575, T=758		C=237/338, T=318/440	2	
chr5:176516631	G/A	G	SNV		FGFR4	exonic	1								52.70	p.Val10Ile		1998	G=0.473, A=0.527		Present				+	2	NM_213647.1	c.28G>A	missense	-0.41	0.35	29.0	0.0	Immunoglobulin I-set domain,Immunoglobulin V-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs1966265		0.249 (ref)	0.227	0.0611	0.1708	YES	ATP binding,alveolar secondary septum development,cell migration,cell-cell junction,cytoplasm,endoplasmic reticulum,endosome,extracellular region,fibroblast growth factor 1 binding,fibroblast growth factor 2 binding,fibroblast growth factor binding,fibroblast growth factor receptor signaling pathway,fibroblast growth factor-activated receptor activity,glucose homeostasis,heparin binding,insulin receptor signaling pathway,integral to plasma membrane,lung development,nucleolus,nucleotide binding,nucleus,organ induction,peptidyl-tyrosine phosphorylation,phosphate ion homeostasis,plasma membrane,positive regulation of DNA biosynthetic process,positive regulation of ERK1 and ERK2 cascade,positive regulation of cell proliferation,positive regulation of metalloenzyme activity,positive regulation of proteolysis,protein autophosphorylation,protein tyrosine kinase activity,receptor activity,regulation of bile acid biosynthetic process,regulation of cholesterol homeostasis,regulation of extracellular matrix disassembly,regulation of lipid metabolic process	Palifermin		0.00001	10213.2	G=945, A=1053		G=509/436, A=501/552	5	
chr5:176520243	G/A	G	SNV		FGFR4	exonic	1								47.42	p.Gly388Arg		1993	G=0.5258, A=0.4742		Present				+	9	NM_213647.1	c.1162G>A	missense	2.23	0.0	125.0	0.998	Immunoglobulin I-set domain,Immunoglobulin V-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs351855		0.303 (ref)	0.3006	0.1287	0.2423	YES	ATP binding,alveolar secondary septum development,cell migration,cell-cell junction,cytoplasm,endoplasmic reticulum,endosome,extracellular region,fibroblast growth factor 1 binding,fibroblast growth factor 2 binding,fibroblast growth factor binding,fibroblast growth factor receptor signaling pathway,fibroblast growth factor-activated receptor activity,glucose homeostasis,heparin binding,insulin receptor signaling pathway,integral to plasma membrane,lung development,nucleolus,nucleotide binding,nucleus,organ induction,peptidyl-tyrosine phosphorylation,phosphate ion homeostasis,plasma membrane,positive regulation of DNA biosynthetic process,positive regulation of ERK1 and ERK2 cascade,positive regulation of cell proliferation,positive regulation of metalloenzyme activity,positive regulation of proteolysis,protein autophosphorylation,protein tyrosine kinase activity,receptor activity,regulation of bile acid biosynthetic process,regulation of cholesterol homeostasis,regulation of extracellular matrix disassembly,regulation of lipid metabolic process	Palifermin	pathogenic	0.00001	8600.7	G=1048, A=945		G=518/530, A=411/534	3	
chr6:41903782	AG/CA	AG	MNV		CCND3	exonic	2								32.80	p.Ser259Ala		1997	AG=0.672, CA=0.328		Present				-	5	NM_001760.4	c.774_775delCTinsTG	synonymous, missense	-0.25,-2.53	0.59	99.0	0.0	Cyclin	rs1051130,rs3218102		0.035,0.415	0.4535	0.2238	0.3757	YES	T cell proliferation,cell division,cyclin-dependent protein kinase activity,cyclin-dependent protein kinase holoenzyme complex,cytoplasm,membrane,nucleus,positive regulation of cyclin-dependent protein kinase activity,positive regulation of protein phosphorylation,protein binding,protein kinase binding,regulation of cell cycle,signal transduction			0.00001	4686.75	AG=1342, CA=655		AG=659/683, CA=318/337	1	
chr6:117622184	G/C	G	SNV		ROS1	exonic	1								67.54	p.Ser2229Cys		878	G=0.3246, C=0.6754		Present				-	42	NM_002944.2	c.6686C>G	missense	0.09	1.0	112.0	0.0	Fibronectin type III domain,Protein kinase domain,Protein tyrosine kinase	rs619203		0.16 (ref)	0.2598	0.0742	0.1969	YES	ATP binding,cell differentiation,cell growth,cell proliferation,columnar/cuboidal epithelial cell development,integral to membrane,membrane fraction,negative regulation of gene expression,nucleotide binding,plasma membrane,protein phosphatase binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of ERK1 and ERK2 cascade,regulation of TOR signaling cascade,regulation of phosphate transport,spermatogenesis,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	6653.45	G=285, C=593		G=145/140, C=260/333	2	
chr6:117622188	T/G	T	SNV		ROS1	exonic	1								67.73	p.Lys2228Gln		880	T=0.3227, G=0.6773		Present				-	42	NM_002944.2	c.6682A>C	missense	1.45	0.36	53.0	0.0	Fibronectin type III domain,Protein kinase domain,Protein tyrosine kinase	rs529156		0.16 (ref)	0.2598	0.0742	0.1969	YES	ATP binding,cell differentiation,cell growth,cell proliferation,columnar/cuboidal epithelial cell development,integral to membrane,membrane fraction,negative regulation of gene expression,nucleotide binding,plasma membrane,protein phosphatase binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of ERK1 and ERK2 cascade,regulation of TOR signaling cascade,regulation of phosphate transport,spermatogenesis,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	6700.35	T=284, G=596		T=145/139, G=261/335	2	
chr6:117622233	C/T	C	SNV		ROS1	exonic	1								67.58	p.Asp2213Asn		873	C=0.3242, T=0.6758		Present				-	42	NM_002944.2	c.6637G>A	missense	0.75	0.22	23.0	0.009	Fibronectin type III domain,Protein kinase domain,Protein tyrosine kinase	rs529038		0.158	0.2594	0.0688	0.1948	YES	ATP binding,cell differentiation,cell growth,cell proliferation,columnar/cuboidal epithelial cell development,integral to membrane,membrane fraction,negative regulation of gene expression,nucleotide binding,plasma membrane,protein phosphatase binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of ERK1 and ERK2 cascade,regulation of TOR signaling cascade,regulation of phosphate transport,spermatogenesis,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	6613.35	C=283, T=590		C=142/141, T=254/336	2	
chr6:152129077	T/C	T	SNV		ESR1	exonic	1								62.63	p.(=)		1124	T=0.3737, C=0.6263		Present				+	2	NM_001122740.1	c.30T>C	synonymous	-1.28				Ligand-binding domain of nuclear hormone receptor,Oestrogen receptor,Zinc finger	rs2077647		0.432 (ref)	0.4769	0.4828	0.4789	YES	Sertoli cell proliferation,T-tubule,androgen metabolic process,antral ovarian follicle growth,beta-catenin binding,cellular response to estrogen stimulus,chromatin binding,chromatin remodeling complex,cytoplasm,enzyme binding,epithelial cell development,epithelial cell proliferation involved in mammary gland duct elongation,estrogen receptor activity,estrogen response element binding,gene expression,hormone binding,intracellular estrogen receptor signaling pathway,mammary gland alveolus development,mammary gland branching involved in pregnancy,membrane,metal ion binding,mitochondrial part,neuron projection,neuroprotection,nitric-oxide synthase regulator activity,nucleoplasm,nucleus,osteoblast development,perikaryon,perinuclear region of cytoplasm,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of epidermal growth factor receptor signaling pathway,positive regulation of fibroblast proliferation,positive regulation of retinoic acid receptor signaling pathway,positive regulation of survival gene product expression,positive regulation of transcription from RNA polymerase II promoter,prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,prostate epithelial cord elongation,protein binding,protein complex binding,receptor activity,regulation of apoptotic process,regulation of branching involved in prostate gland morphogenesis,regulation of transcription, DNA-dependent,response to estradiol stimulus,response to estrogen stimulus,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,signal transduction,steroid binding,steroid hormone mediated signaling pathway,steroid hormone receptor activity,terminal button,transcription factor binding,transcription, DNA-dependent,type 1 metabotropic glutamate receptor binding,uterus development,vagina development,zinc ion binding	(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-4-(2-PYRROLIDIN-1-YLETHOXY)PHENYLCHROMAN-6-OL,(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-9-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(9ALPHA,13BETA,17BETA)-2-(1Z)-BUT-1-EN-1-YLESTRA-1,3,5(10)-TRIENE-3,17-DIOL,(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL,1-4-(Octahydro-Pyrido1,2-aPyrazin-2-Yl)-Phenyl-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,17-METHYL-17-ALPHA-DIHYDROEQUILENIN,2-AMINO-1-METHYL-6-PHENYLIMIDAZO4,5-BPYRIDINE,2-Phenyl-1-4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,4-(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(2-amino-1-methyl-1H-imidazo4,5-bpyridin-6-yl)phenol,4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL,4-1-allyl-7-(trifluoromethyl)-1H-indazol-3-ylbenzene-1,3-diol,5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YLACETONITRILE,Allylestrenol,Chlorotrianisene,Clomifene,Compound 18,Compound 19,Compound 4-D,Conjugated Estrogens,DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO2.2.1HEPT-5-ENE-2,3-DICARBOXYLATE,Danazol,Desogestrel,Dienestrol,Diethylstilbestrol,Estradiol,Estramustine,Estriol,Estrone,Estropipate,Ethinyl Estradiol,Ethynodiol Diacetate,Etonogestrel,Fluoxymesterone,Fulvestrant,Genistein,Levonorgestrel,Medroxyprogesterone,Melatonin,Mestranol,N-(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE,Naloxone,Norgestimate,Progesterone,Quinestrol,RALOXIFENE CORE,Raloxifene,Tamoxifen,Toremifene,Trilostane,dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo2.2.1hepta-2,5-diene-2,3-dicarboxylate		0.00001	7538.23	T=420, C=704		T=231/189, C=392/312	1	
chr6:152201875	C/C	T	SNV		ESR1	exonic	1								100.00	p.(=)		2000	T=0.0, C=1.0		Present				+	4	NM_001122740.1	c.729T>C	synonymous	0.22				Ligand-binding domain of nuclear hormone receptor,Oestrogen receptor,Zinc finger	rs4986934		0.018 (ref)	0.04	0.0082	0.0292	YES	Sertoli cell proliferation,T-tubule,androgen metabolic process,antral ovarian follicle growth,beta-catenin binding,cellular response to estrogen stimulus,chromatin binding,chromatin remodeling complex,cytoplasm,enzyme binding,epithelial cell development,epithelial cell proliferation involved in mammary gland duct elongation,estrogen receptor activity,estrogen response element binding,gene expression,hormone binding,intracellular estrogen receptor signaling pathway,mammary gland alveolus development,mammary gland branching involved in pregnancy,membrane,metal ion binding,mitochondrial part,neuron projection,neuroprotection,nitric-oxide synthase regulator activity,nucleoplasm,nucleus,osteoblast development,perikaryon,perinuclear region of cytoplasm,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of epidermal growth factor receptor signaling pathway,positive regulation of fibroblast proliferation,positive regulation of retinoic acid receptor signaling pathway,positive regulation of survival gene product expression,positive regulation of transcription from RNA polymerase II promoter,prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,prostate epithelial cord elongation,protein binding,protein complex binding,receptor activity,regulation of apoptotic process,regulation of branching involved in prostate gland morphogenesis,regulation of transcription, DNA-dependent,response to estradiol stimulus,response to estrogen stimulus,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,signal transduction,steroid binding,steroid hormone mediated signaling pathway,steroid hormone receptor activity,terminal button,transcription factor binding,transcription, DNA-dependent,type 1 metabotropic glutamate receptor binding,uterus development,vagina development,zinc ion binding	(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-4-(2-PYRROLIDIN-1-YLETHOXY)PHENYLCHROMAN-6-OL,(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-9-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(9ALPHA,13BETA,17BETA)-2-(1Z)-BUT-1-EN-1-YLESTRA-1,3,5(10)-TRIENE-3,17-DIOL,(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL,1-4-(Octahydro-Pyrido1,2-aPyrazin-2-Yl)-Phenyl-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,17-METHYL-17-ALPHA-DIHYDROEQUILENIN,2-AMINO-1-METHYL-6-PHENYLIMIDAZO4,5-BPYRIDINE,2-Phenyl-1-4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,4-(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(2-amino-1-methyl-1H-imidazo4,5-bpyridin-6-yl)phenol,4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL,4-1-allyl-7-(trifluoromethyl)-1H-indazol-3-ylbenzene-1,3-diol,5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YLACETONITRILE,Allylestrenol,Chlorotrianisene,Clomifene,Compound 18,Compound 19,Compound 4-D,Conjugated Estrogens,DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO2.2.1HEPT-5-ENE-2,3-DICARBOXYLATE,Danazol,Desogestrel,Dienestrol,Diethylstilbestrol,Estradiol,Estramustine,Estriol,Estrone,Estropipate,Ethinyl Estradiol,Ethynodiol Diacetate,Etonogestrel,Fluoxymesterone,Fulvestrant,Genistein,Levonorgestrel,Medroxyprogesterone,Melatonin,Mestranol,N-(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE,Naloxone,Norgestimate,Progesterone,Quinestrol,RALOXIFENE CORE,Raloxifene,Tamoxifen,Toremifene,Trilostane,dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo2.2.1hepta-2,5-diene-2,3-dicarboxylate		0.00001	30496.9	T=0, C=2000		T=0/0, C=837/1163	1	
chr6:152265522	G/C	G	SNV		ESR1	exonic	1								57.27	p.(=)		1989	G=0.4274, C=0.5726		Present				+	5	NM_001122740.1	c.975G>C	synonymous	-0.42				Ligand-binding domain of nuclear hormone receptor,Oestrogen receptor,Zinc finger	rs1801132		0.262 (ref)	0.2257	0.1074	0.1856	YES	Sertoli cell proliferation,T-tubule,androgen metabolic process,antral ovarian follicle growth,beta-catenin binding,cellular response to estrogen stimulus,chromatin binding,chromatin remodeling complex,cytoplasm,enzyme binding,epithelial cell development,epithelial cell proliferation involved in mammary gland duct elongation,estrogen receptor activity,estrogen response element binding,gene expression,hormone binding,intracellular estrogen receptor signaling pathway,mammary gland alveolus development,mammary gland branching involved in pregnancy,membrane,metal ion binding,mitochondrial part,neuron projection,neuroprotection,nitric-oxide synthase regulator activity,nucleoplasm,nucleus,osteoblast development,perikaryon,perinuclear region of cytoplasm,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of epidermal growth factor receptor signaling pathway,positive regulation of fibroblast proliferation,positive regulation of retinoic acid receptor signaling pathway,positive regulation of survival gene product expression,positive regulation of transcription from RNA polymerase II promoter,prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,prostate epithelial cord elongation,protein binding,protein complex binding,receptor activity,regulation of apoptotic process,regulation of branching involved in prostate gland morphogenesis,regulation of transcription, DNA-dependent,response to estradiol stimulus,response to estrogen stimulus,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,signal transduction,steroid binding,steroid hormone mediated signaling pathway,steroid hormone receptor activity,terminal button,transcription factor binding,transcription, DNA-dependent,type 1 metabotropic glutamate receptor binding,uterus development,vagina development,zinc ion binding	(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-4-(2-PYRROLIDIN-1-YLETHOXY)PHENYLCHROMAN-6-OL,(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-9-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(9ALPHA,13BETA,17BETA)-2-(1Z)-BUT-1-EN-1-YLESTRA-1,3,5(10)-TRIENE-3,17-DIOL,(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL,1-4-(Octahydro-Pyrido1,2-aPyrazin-2-Yl)-Phenyl-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,17-METHYL-17-ALPHA-DIHYDROEQUILENIN,2-AMINO-1-METHYL-6-PHENYLIMIDAZO4,5-BPYRIDINE,2-Phenyl-1-4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,4-(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(2-amino-1-methyl-1H-imidazo4,5-bpyridin-6-yl)phenol,4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL,4-1-allyl-7-(trifluoromethyl)-1H-indazol-3-ylbenzene-1,3-diol,5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YLACETONITRILE,Allylestrenol,Chlorotrianisene,Clomifene,Compound 18,Compound 19,Compound 4-D,Conjugated Estrogens,DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO2.2.1HEPT-5-ENE-2,3-DICARBOXYLATE,Danazol,Desogestrel,Dienestrol,Diethylstilbestrol,Estradiol,Estramustine,Estriol,Estrone,Estropipate,Ethinyl Estradiol,Ethynodiol Diacetate,Etonogestrel,Fluoxymesterone,Fulvestrant,Genistein,Levonorgestrel,Medroxyprogesterone,Melatonin,Mestranol,N-(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE,Naloxone,Norgestimate,Progesterone,Quinestrol,RALOXIFENE CORE,Raloxifene,Tamoxifen,Toremifene,Trilostane,dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo2.2.1hepta-2,5-diene-2,3-dicarboxylate		0.00001	11377.6	G=850, C=1139		G=471/379, C=574/565	1	
chr7:6013049	G/G	C	SNV		PMS2	exonic	1								97.83	p.Gly857Ala		552	C=0.0217, G=0.9783		Present				-	15	NM_000535.5	c.2570G>C	missense	0.33	0.19	60.0	0.0	DNA mismatch repair protein,Histidine kinase-	rs1802683		0.173 (ref)				YES	ATP binding,ATP catabolic process,ATPase activity,DNA binding,MutLalpha complex,MutSalpha complex binding,endonuclease activity,hydrolase activity,mismatch repair,mismatched DNA binding,nucleus,protein binding,reciprocal meiotic recombination,response to drug,single base insertion or deletion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments	Adenosine-5'-Diphosphate,Phosphothiophosphoric Acid-Adenylate Ester	non-pathogenic,probable-non-pathogenic	0.00001	7981.77	C=12, G=540		C=3/9, G=274/266	3	
chr7:6026775	C/C	T	SNV		PMS2	exonic	1								100.00	p.Lys541Glu		1986	T=0.0, C=1.0		Present				-	11	NM_000535.5	c.1621A>G	missense	0.74	1.0	56.0	0.0	DNA mismatch repair protein,Histidine kinase-	rs2228006		0.121 (ref)	0.1543	0.0815	0.1296	YES	ATP binding,ATP catabolic process,ATPase activity,DNA binding,MutLalpha complex,MutSalpha complex binding,endonuclease activity,hydrolase activity,mismatch repair,mismatched DNA binding,nucleus,protein binding,reciprocal meiotic recombination,response to drug,single base insertion or deletion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments	Adenosine-5'-Diphosphate,Phosphothiophosphoric Acid-Adenylate Ester		0.00001	30024.2	T=0, C=1986		T=0/0, C=1003/983	4	
chr7:6026988	G/A	G	SNV		PMS2	exonic	1								51.85	p.Pro470Ser		2000	G=0.4815, A=0.5185		Present				-	11	NM_000535.5	c.1408C>T	missense	0.39	0.51	74.0	0.002	DNA mismatch repair protein,Histidine kinase-	rs1805321		0.394 (ref)	0.4209	0.2819	0.3738	YES	ATP binding,ATP catabolic process,ATPase activity,DNA binding,MutLalpha complex,MutSalpha complex binding,endonuclease activity,hydrolase activity,mismatch repair,mismatched DNA binding,nucleus,protein binding,reciprocal meiotic recombination,response to drug,single base insertion or deletion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments	Adenosine-5'-Diphosphate,Phosphothiophosphoric Acid-Adenylate Ester	non-pathogenic	0.00001	9965.59	G=963, A=1037		G=461/502, A=534/503	2	
chr7:6036980	C/C	G	SNV		PMS2	exonic	1								100.00	p.(=)		1992	G=0.0, C=1.0		Present				-	7	NM_000535.5	c.780C>G	synonymous	-5.63				DNA mismatch repair protein,Histidine kinase-	rs1805319		0.157 (ref)	0.1852	0.1586	0.1762	YES	ATP binding,ATP catabolic process,ATPase activity,DNA binding,MutLalpha complex,MutSalpha complex binding,endonuclease activity,hydrolase activity,mismatch repair,mismatched DNA binding,nucleus,protein binding,reciprocal meiotic recombination,response to drug,single base insertion or deletion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments	Adenosine-5'-Diphosphate,Phosphothiophosphoric Acid-Adenylate Ester	non-pathogenic	0.00001	30351.3	G=0, C=1992		G=0/0, C=977/1015	2	
chr7:6045627	C/T	C	SNV		PMS2	exonic	1								47.65	p.Arg20Gln		2000	C=0.5235, T=0.4765		Present				-	2	NM_000535.5	c.59G>A	missense	0.08	0.2	43.0	0.5	DNA mismatch repair protein,Histidine kinase-	rs10254120		0.07 (ref)	0.0592	0.0906	0.0709	YES	ATP binding,ATP catabolic process,ATPase activity,DNA binding,MutLalpha complex,MutSalpha complex binding,endonuclease activity,hydrolase activity,mismatch repair,mismatched DNA binding,nucleus,protein binding,reciprocal meiotic recombination,response to drug,single base insertion or deletion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments	Adenosine-5'-Diphosphate,Phosphothiophosphoric Acid-Adenylate Ester	non-pathogenic	0.00001	8700.25	C=1047, T=953		C=515/532, T=459/494	2	
chr7:55233089	C/T	C	SNV		EGFR	exonic	1								52.68	p.(=)		1999	C=0.4732, T=0.5268		Present				+	15	NM_005228.3	c.1839C>T	synonymous	0.33				Furin-like cysteine rich region,Protein kinase domain,Protein tyrosine kinase,Receptor L domain	rs17290169		0.041 (ref)	0.0595	0.0552	0.058	YES	AP-2 adaptor complex,ATP binding,Golgi apparatus,Golgi membrane,MAP/ERK kinase kinase activity,Shc-EGFR complex,actin filament binding,activation of phospholipase A2 activity by calcium-mediated signaling,activation of phospholipase C activity,axon guidance,basolateral plasma membrane,cell morphogenesis,cell proliferation,cell surface receptor linked signaling pathway,cell-cell adhesion,cerebral cortex cell migration,cytoplasm,digestive tract morphogenesis,double-stranded DNA binding,embryonic placenta development,endocytic vesicle,endoplasmic reticulum,endoplasmic reticulum membrane,endosome,endosome membrane,enzyme binding,epidermal growth factor receptor signaling pathway,epidermal growth factor-activated receptor activity,extracellular region,extracellular space,hair follicle development,identical protein binding,integral to membrane,intracellular,membrane,membrane raft,morphogenesis of an epithelial fold,multicellular organismal development,negative regulation of apoptotic process,negative regulation of epidermal growth factor receptor signaling pathway,negative regulation of protein catabolic process,nitric-oxide synthase regulator activity,nuclear membrane,nucleotide binding,nucleus,ossification,perinuclear region of cytoplasm,plasma membrane,positive regulation of DNA repair,positive regulation of DNA replication,positive regulation of MAP kinase activity,positive regulation of catenin import into nucleus,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of cyclin-dependent protein kinase activity involved in G1/S,positive regulation of epithelial cell proliferation,positive regulation of fibroblast proliferation,positive regulation of nitric oxide biosynthetic process,positive regulation of phosphorylation,positive regulation of protein kinase B signaling cascade,protein autophosphorylation,protein binding,protein heterodimerization activity,protein insertion into membrane,protein phosphatase binding,protein tyrosine kinase activity,receptor activity,receptor signaling protein tyrosine kinase activity,regulation of nitric-oxide synthase activity,regulation of peptidyl-tyrosine phosphorylation,response to UV-A,response to stress,salivary gland morphogenesis,signal transducer activity,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane signaling receptor activity	Cetuximab,Erlotinib,Flavopiridol,Gefitinib,Lapatinib,Lidocaine,N-4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL-ACRYLAMIDE,Panitumumab,S-{3-(4-ANILINOQUINAZOLIN-6-YL)AMINO-3-OXOPROPYL}-L-CYSTEINE,Trastuzumab,ZD-6474		0.00001	10217.1	C=946, T=1053		C=488/458, T=518/535	2	
chr7:55249063	A/A	G	SNV		EGFR,EGFR-AS1	exonic, exonic_nc	1								100.00	p.(=)		1995	G=0.0, A=1.0		Present				+, -	20	NM_005228.3, NR_047551.1	c.2361G>A	synonymous	2.8				Furin-like cysteine rich region,Protein kinase domain,Protein tyrosine kinase,Receptor L domain	rs1050171		0.418 (ref)	0.3962	0.4226	0.4576	YES	AP-2 adaptor complex,ATP binding,Golgi apparatus,Golgi membrane,MAP/ERK kinase kinase activity,Shc-EGFR complex,actin filament binding,activation of phospholipase A2 activity by calcium-mediated signaling,activation of phospholipase C activity,axon guidance,basolateral plasma membrane,cell morphogenesis,cell proliferation,cell surface receptor linked signaling pathway,cell-cell adhesion,cerebral cortex cell migration,cytoplasm,digestive tract morphogenesis,double-stranded DNA binding,embryonic placenta development,endocytic vesicle,endoplasmic reticulum,endoplasmic reticulum membrane,endosome,endosome membrane,enzyme binding,epidermal growth factor receptor signaling pathway,epidermal growth factor-activated receptor activity,extracellular region,extracellular space,hair follicle development,identical protein binding,integral to membrane,intracellular,membrane,membrane raft,morphogenesis of an epithelial fold,multicellular organismal development,negative regulation of apoptotic process,negative regulation of epidermal growth factor receptor signaling pathway,negative regulation of protein catabolic process,nitric-oxide synthase regulator activity,nuclear membrane,nucleotide binding,nucleus,ossification,perinuclear region of cytoplasm,plasma membrane,positive regulation of DNA repair,positive regulation of DNA replication,positive regulation of MAP kinase activity,positive regulation of catenin import into nucleus,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of cyclin-dependent protein kinase activity involved in G1/S,positive regulation of epithelial cell proliferation,positive regulation of fibroblast proliferation,positive regulation of nitric oxide biosynthetic process,positive regulation of phosphorylation,positive regulation of protein kinase B signaling cascade,protein autophosphorylation,protein binding,protein heterodimerization activity,protein insertion into membrane,protein phosphatase binding,protein tyrosine kinase activity,receptor activity,receptor signaling protein tyrosine kinase activity,regulation of nitric-oxide synthase activity,regulation of peptidyl-tyrosine phosphorylation,response to UV-A,response to stress,salivary gland morphogenesis,signal transducer activity,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane signaling receptor activity	Cetuximab,Erlotinib,Flavopiridol,Gefitinib,Lapatinib,Lidocaine,N-4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL-ACRYLAMIDE,Panitumumab,S-{3-(4-ANILINOQUINAZOLIN-6-YL)AMINO-3-OXOPROPYL}-L-CYSTEINE,Trastuzumab,ZD-6474		0.00001	30388.4	G=0, A=1995		G=0/0, A=996/999	1	
chr7:55266417	C/C	T	SNV		EGFR	exonic	1								100.00	p.(=)		1993	T=0.0, C=1.0		Present				+	23	NM_005228.3	c.2709T>C	synonymous	-1.92				Furin-like cysteine rich region,Protein kinase domain,Protein tyrosine kinase,Receptor L domain	rs1140475		0.095 (ref)	0.1267	0.0801	0.1109	YES	AP-2 adaptor complex,ATP binding,Golgi apparatus,Golgi membrane,MAP/ERK kinase kinase activity,Shc-EGFR complex,actin filament binding,activation of phospholipase A2 activity by calcium-mediated signaling,activation of phospholipase C activity,axon guidance,basolateral plasma membrane,cell morphogenesis,cell proliferation,cell surface receptor linked signaling pathway,cell-cell adhesion,cerebral cortex cell migration,cytoplasm,digestive tract morphogenesis,double-stranded DNA binding,embryonic placenta development,endocytic vesicle,endoplasmic reticulum,endoplasmic reticulum membrane,endosome,endosome membrane,enzyme binding,epidermal growth factor receptor signaling pathway,epidermal growth factor-activated receptor activity,extracellular region,extracellular space,hair follicle development,identical protein binding,integral to membrane,intracellular,membrane,membrane raft,morphogenesis of an epithelial fold,multicellular organismal development,negative regulation of apoptotic process,negative regulation of epidermal growth factor receptor signaling pathway,negative regulation of protein catabolic process,nitric-oxide synthase regulator activity,nuclear membrane,nucleotide binding,nucleus,ossification,perinuclear region of cytoplasm,plasma membrane,positive regulation of DNA repair,positive regulation of DNA replication,positive regulation of MAP kinase activity,positive regulation of catenin import into nucleus,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of cyclin-dependent protein kinase activity involved in G1/S,positive regulation of epithelial cell proliferation,positive regulation of fibroblast proliferation,positive regulation of nitric oxide biosynthetic process,positive regulation of phosphorylation,positive regulation of protein kinase B signaling cascade,protein autophosphorylation,protein binding,protein heterodimerization activity,protein insertion into membrane,protein phosphatase binding,protein tyrosine kinase activity,receptor activity,receptor signaling protein tyrosine kinase activity,regulation of nitric-oxide synthase activity,regulation of peptidyl-tyrosine phosphorylation,response to UV-A,response to stress,salivary gland morphogenesis,signal transducer activity,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane signaling receptor activity	Cetuximab,Erlotinib,Flavopiridol,Gefitinib,Lapatinib,Lidocaine,N-4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL-ACRYLAMIDE,Panitumumab,S-{3-(4-ANILINOQUINAZOLIN-6-YL)AMINO-3-OXOPROPYL}-L-CYSTEINE,Trastuzumab,ZD-6474		0.00001	30367.4	T=0, C=1993		T=0/0, C=1044/949	1	
chr7:55269475		G	GENE_EXPRESSION		EGFR								EGFR.E26E27				183				Present			2.0858e-10																						0.0					
chr7:116395569		C	GENE_EXPRESSION		MET								MET.E7E8				18406				Present			2.0979e-08																						0.0					
chr7:116411990	C/T	C	SNV		MET	exonic	1	Hotspot	Gain-of-function			HS	COSM707		43.82	p.Thr1010Ile		1919	C=0.5618, T=0.4382		Present				+	14	NM_001127500.1	c.3029C>T	missense	2.84	0.06	89.0	1.0	IPT/TIG domain,Plexin repeat,Protein kinase domain,Protein tyrosine kinase,Sema domain	rs56391007		0.006 (ref)	0.0125	0.0011	0.0089		ATP binding,axon guidance,basal plasma membrane,cell proliferation,cell surface receptor linked signaling pathway,hepatocyte growth factor receptor signaling pathway,hepatocyte growth factor-activated receptor activity,integral to membrane,integral to plasma membrane,multicellular organismal development,nucleotide binding,plasma membrane,protein binding,protein tyrosine kinase activity,receptor activity,signal transduction	1-(2-NITROPHENYL)SULFONYL-1H-PYRROLO3,2-BPYRIDINE-6-CARBOXAMIDE,1-(4-fluorophenyl)-N-3-fluoro-4-(1H-pyrrolo2,3-bpyridin-4-yloxy)phenyl-2-oxo-1,2-dihydropyridine-3-carboxamide,2-(4-fluorophenyl)-N-{3-fluoro-4-(1H-pyrrolo2,3-bpyridin-4-yloxy)phenylcarbamoyl}acetamide,3-(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine,3-3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-ylphenol,6-{6-(1-methyl-1H-pyrazol-4-yl)1,2,4triazolo4,3-bpyridazin-3-ylsulfanyl}quinoline,K-252a,N-(3-chlorophenyl)-N-methyl-2-oxo-3-(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl-2H-indole-5-sulfonamide,N-({4-(2-aminopyridin-4-yl)oxy-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide	non-pathogenic	0.00001	6734.01	C=1078, T=841		C=466/612, T=372/469	1	
chr7:116415165		G	GENE_EXPRESSION		MET								MET.E15E16				683				Present			7.7848e-10																						0.0					
chr7:116435768	C/T	C	SNV		MET	exonic	1								51.19	p.(=)		1979	C=0.4881, T=0.5119		Present				+	20	NM_001127500.1	c.3912C>T	synonymous	-3.37				IPT/TIG domain,Plexin repeat,Protein kinase domain,Protein tyrosine kinase,Sema domain	rs41736		0.372 (ref)	0.4243	0.1041	0.3235	YES	ATP binding,axon guidance,basal plasma membrane,cell proliferation,cell surface receptor linked signaling pathway,hepatocyte growth factor receptor signaling pathway,hepatocyte growth factor-activated receptor activity,integral to membrane,integral to plasma membrane,multicellular organismal development,nucleotide binding,plasma membrane,protein binding,protein tyrosine kinase activity,receptor activity,signal transduction	1-(2-NITROPHENYL)SULFONYL-1H-PYRROLO3,2-BPYRIDINE-6-CARBOXAMIDE,1-(4-fluorophenyl)-N-3-fluoro-4-(1H-pyrrolo2,3-bpyridin-4-yloxy)phenyl-2-oxo-1,2-dihydropyridine-3-carboxamide,2-(4-fluorophenyl)-N-{3-fluoro-4-(1H-pyrrolo2,3-bpyridin-4-yloxy)phenylcarbamoyl}acetamide,3-(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine,3-3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-ylphenol,6-{6-(1-methyl-1H-pyrazol-4-yl)1,2,4triazolo4,3-bpyridazin-3-ylsulfanyl}quinoline,K-252a,N-(3-chlorophenyl)-N-methyl-2-oxo-3-(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl-2H-indole-5-sulfonamide,N-({4-(2-aminopyridin-4-yl)oxy-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide		0.00001	9659.87	C=966, T=1013		C=546/420, T=542/471	1	
chr7:116436022	G/A	G	SNV		MET	exonic	1								50.98	p.(=)		1999	G=0.4902, A=0.5098		Present				+	21	NM_001127500.1	c.4071G>A	synonymous	-3.55				IPT/TIG domain,Plexin repeat,Protein kinase domain,Protein tyrosine kinase,Sema domain	rs2023748		0.373 (ref)	0.4268	0.1029	0.3225	YES	ATP binding,axon guidance,basal plasma membrane,cell proliferation,cell surface receptor linked signaling pathway,hepatocyte growth factor receptor signaling pathway,hepatocyte growth factor-activated receptor activity,integral to membrane,integral to plasma membrane,multicellular organismal development,nucleotide binding,plasma membrane,protein binding,protein tyrosine kinase activity,receptor activity,signal transduction	1-(2-NITROPHENYL)SULFONYL-1H-PYRROLO3,2-BPYRIDINE-6-CARBOXAMIDE,1-(4-fluorophenyl)-N-3-fluoro-4-(1H-pyrrolo2,3-bpyridin-4-yloxy)phenyl-2-oxo-1,2-dihydropyridine-3-carboxamide,2-(4-fluorophenyl)-N-{3-fluoro-4-(1H-pyrrolo2,3-bpyridin-4-yloxy)phenylcarbamoyl}acetamide,3-(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine,3-3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-ylphenol,6-{6-(1-methyl-1H-pyrazol-4-yl)1,2,4triazolo4,3-bpyridazin-3-ylsulfanyl}quinoline,K-252a,N-(3-chlorophenyl)-N-methyl-2-oxo-3-(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl-2H-indole-5-sulfonamide,N-({4-(2-aminopyridin-4-yl)oxy-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide		0.00001	9688.75	G=980, A=1019		G=561/419, A=596/423	1	
chr7:140439646		T	GENE_EXPRESSION		BRAF								BRAF.E16E17				410				Present			4.6732e-10																						0.0					
chr7:140449150	T/C	T	SNV		BRAF	exonic	1								47.20	p.(=)		2000	T=0.528, C=0.472		Present				-	16	NM_004333.4	c.1929A>G	synonymous	-0.01				C1-like domain,Phorbol esters/diacylglycerol binding domain (C1 domain),Protein kinase domain,Protein tyrosine kinase,Raf-like Ras-binding domain	rs9648696		0.28 (ref)	0.1463	0.3409	0.32	YES	ATP binding,MAP kinase kinase kinase activity,activation of MAPKK activity,anti-apoptosis,cytoplasm,cytosol,metal ion binding,mitogen-activated protein kinase kinase binding,negative regulation of apoptotic process,negative regulation of neuron apoptosis,nerve growth factor receptor signaling pathway,nucleotide binding,nucleus,organ morphogenesis,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of peptidyl-serine phosphorylation,protein binding,protein heterodimerization activity,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,receptor signaling protein activity,response to cAMP,response to peptide hormone stimulus,small GTPase mediated signal transduction,soluble fraction,synaptic transmission,synaptosome	(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime,N-{2,4-difluoro-3-(5-pyridin-3-yl-1H-pyrrolo2,3-bpyridin-3-yl)carbonylphenyl}ethanesulfonamide,N-{3-(5-chloro-1H-pyrrolo2,3-bpyridin-3-yl)carbonyl-2,4-difluorophenyl}propane-1-sulfonamide,Sorafenib		0.00001	8564.81	T=1056, C=944		T=525/531, C=491/453	2	
chr7:140481441		T	GENE_EXPRESSION		BRAF								BRAF-BRAF.B3B11				35				Present			3.9893e-11																						0.0					
chr7:140487347		C	GENE_EXPRESSION		BRAF								BRAF-BRAF.B3B9				2556				Present			2.9133e-09																						0.0					
chr7:140501300		C	GENE_EXPRESSION		BRAF								BRAF.E5E6				2864				Present			3.2644e-09																						0.0					
chr8:90958422	T/C	T	SNV		NBN	exonic	1								64.80	p.(=)		2000	T=0.352, C=0.648		Present				-	13	NM_002485.4	c.2016A>G	synonymous	-1.06				BRCA1 C Terminus (BRCT) domain,DNA damage repair protein Nbs1,FHA domain	rs1061302		0.328 (ref)	0.3132	0.2276	0.2842	YES	ATP-dependent DNA helicase activity,DNA damage checkpoint,DNA damage response, signal transduction by p53 class mediator,DNA duplex unwinding,DNA repair,G2/M transition checkpoint,Mre11 complex,apoptotic process,blastocyst growth,cell cycle,cell cycle arrest,chromosome,damaged DNA binding,double-strand break repair,double-strand break repair via homologous recombination,in utero embryonic development,intracellular,isotype switching,meiosis,mitotic cell cycle G1/S transition checkpoint,mitotic cell cycle G2/M transition DNA damage checkpoint,negative regulation of neuron differentiation,neuromuscular process controlling balance,nuclear chromosome, telomeric region,nuclear inclusion body,nucleolus,nucleoplasm,nucleus,positive regulation of cell proliferation,positive regulation of kinase activity,positive regulation of protein autophosphorylation,protein N-terminus binding,protein binding,regulation of DNA-dependent DNA replication initiation,regulation of fibroblast proliferation,replication fork,response to drug,telomere maintenance,transcription factor binding			0.00001	14266.4	T=704, C=1296		T=323/381, C=647/649	1	
chr8:90967711	A/G	A	SNV		NBN	exonic	1								65.18	p.(=)		1999	A=0.3482, G=0.6518		Present				-	10	NM_002485.4	c.1197T>C	synonymous	-0.48				BRCA1 C Terminus (BRCT) domain,DNA damage repair protein Nbs1,FHA domain	rs709816		0.424 (ref)	0.3559	0.2473	0.4903	YES	ATP-dependent DNA helicase activity,DNA damage checkpoint,DNA damage response, signal transduction by p53 class mediator,DNA duplex unwinding,DNA repair,G2/M transition checkpoint,Mre11 complex,apoptotic process,blastocyst growth,cell cycle,cell cycle arrest,chromosome,damaged DNA binding,double-strand break repair,double-strand break repair via homologous recombination,in utero embryonic development,intracellular,isotype switching,meiosis,mitotic cell cycle G1/S transition checkpoint,mitotic cell cycle G2/M transition DNA damage checkpoint,negative regulation of neuron differentiation,neuromuscular process controlling balance,nuclear chromosome, telomeric region,nuclear inclusion body,nucleolus,nucleoplasm,nucleus,positive regulation of cell proliferation,positive regulation of kinase activity,positive regulation of protein autophosphorylation,protein N-terminus binding,protein binding,regulation of DNA-dependent DNA replication initiation,regulation of fibroblast proliferation,replication fork,response to drug,telomere maintenance,transcription factor binding			0.00001	14397.3	A=696, G=1303		A=375/321, G=710/593	1	
chr8:90990479	C/G	C	SNV		NBN	exonic	1								59.29	p.Glu185Gln		1066	C=0.4071, G=0.5929		Present				-	5	NM_002485.4	c.553G>C	missense	0.09	1.0	29.0	0.0	BRCA1 C Terminus (BRCT) domain,DNA damage repair protein Nbs1,FHA domain	rs1805794		0.333 (ref)	0.3136	0.2338	0.2866	YES	ATP-dependent DNA helicase activity,DNA damage checkpoint,DNA damage response, signal transduction by p53 class mediator,DNA duplex unwinding,DNA repair,G2/M transition checkpoint,Mre11 complex,apoptotic process,blastocyst growth,cell cycle,cell cycle arrest,chromosome,damaged DNA binding,double-strand break repair,double-strand break repair via homologous recombination,in utero embryonic development,intracellular,isotype switching,meiosis,mitotic cell cycle G1/S transition checkpoint,mitotic cell cycle G2/M transition DNA damage checkpoint,negative regulation of neuron differentiation,neuromuscular process controlling balance,nuclear chromosome, telomeric region,nuclear inclusion body,nucleolus,nucleoplasm,nucleus,positive regulation of cell proliferation,positive regulation of kinase activity,positive regulation of protein autophosphorylation,protein N-terminus binding,protein binding,regulation of DNA-dependent DNA replication initiation,regulation of fibroblast proliferation,replication fork,response to drug,telomere maintenance,transcription factor binding			0.00001	6571.46	C=434, G=632		C=218/216, G=283/349	1	
chr8:90995019	C/T	C	SNV		NBN	exonic	1								62.45	p.(=)		2000	C=0.3755, T=0.6245		Present				-	2	NM_002485.4	c.102G>A	synonymous	-0.39				BRCA1 C Terminus (BRCT) domain,DNA damage repair protein Nbs1,FHA domain	rs1063045		0.35 (ref)	0.3147	0.3103	0.3132	YES	ATP-dependent DNA helicase activity,DNA damage checkpoint,DNA damage response, signal transduction by p53 class mediator,DNA duplex unwinding,DNA repair,G2/M transition checkpoint,Mre11 complex,apoptotic process,blastocyst growth,cell cycle,cell cycle arrest,chromosome,damaged DNA binding,double-strand break repair,double-strand break repair via homologous recombination,in utero embryonic development,intracellular,isotype switching,meiosis,mitotic cell cycle G1/S transition checkpoint,mitotic cell cycle G2/M transition DNA damage checkpoint,negative regulation of neuron differentiation,neuromuscular process controlling balance,nuclear chromosome, telomeric region,nuclear inclusion body,nucleolus,nucleoplasm,nucleus,positive regulation of cell proliferation,positive regulation of kinase activity,positive regulation of protein autophosphorylation,protein N-terminus binding,protein binding,regulation of DNA-dependent DNA replication initiation,regulation of fibroblast proliferation,replication fork,response to drug,telomere maintenance,transcription factor binding			0.00001	13431.6	C=751, T=1249		C=396/355, T=617/632	1	
chr9:21970916	C/T	C	SNV		CDKN2A	exonic	1								56.43	p.Ala148Thr		1999	C=0.4357, T=0.5643		Present				-	2	NM_000077.4	c.442G>A	missense	0.4	0.0	58.0	0.351	Cyclin-dependent kinase inhibitor 2a p19Arf N-terminus	rs3731249		0.012 (ref)	0.0321	0.0039	0.0225	YES	G1 phase of mitotic cell cycle,G1/S transition of mitotic cell cycle,NF-kappaB binding,Ras protein signal transduction,cell aging,cell cycle arrest,cell cycle checkpoint,cyclin-dependent protein kinase inhibitor activity,cytoplasm,cytosol,epidermis development,induction of apoptosis,mitotic cell cycle,negative regulation of NF-kappaB transcription factor activity,negative regulation of cell growth,negative regulation of cell proliferation,negative regulation of cell-matrix adhesion,negative regulation of cyclin-dependent protein kinase activity,negative regulation of mammary gland epithelial cell proliferation,negative regulation of phosphorylation,negative regulation of transcription, DNA-dependent,nucleolus,nucleoplasm,nucleus,positive regulation of apoptosis involved in mammary gland involution,positive regulation of cellular senescence,positive regulation of macrophage apoptosis,positive regulation of smooth muscle cell apoptosis,protein binding,protein kinase binding,rRNA transcription,regulation of nucleocytoplasmic transport,replicative senescence,senescence-associated heterochromatin focus,senescence-associated heterochromatin focus assembly,sequence-specific DNA binding transcription factor activity			0.00001	11408.8	C=871, T=1128		C=483/388, T=577/551	1	
chr9:22006119	G/A	G	SNV		CDKN2B,CDKN2B-AS1	intronic_nc, exonic	1								5.88	p.Thr95Met		51	G=0.9412, A=0.0588		Present				+, -	2	NR_047543.1, NM_004936.3	c.284C>T	missense	2.47	0.01	81.0	1.0									G1 phase of mitotic cell cycle,G2/M transition of mitotic cell cycle,cell cycle arrest,cellular response to extracellular stimulus,cellular response to nutrient,cyclin-dependent protein kinase inhibitor activity,cytoplasm,cytosol,megakaryocyte differentiation,mitotic cell cycle,mitotic cell cycle G1/S transition checkpoint,negative regulation of cell proliferation,negative regulation of epithelial cell proliferation,negative regulation of phosphorylation,nucleus,positive regulation of epithelial cell differentiation,positive regulation of transforming growth factor beta receptor signaling pathway,protein binding,protein kinase binding,regulation of cyclin-dependent protein kinase activity,response to cytokine stimulus,response to organic cyclic compound			0.07375	11.3226	G=48, A=3		G=20/28, A=1/2	1	
chr9:139391636	G/A	G	SNV		NOTCH1	exonic	1								54.73	p.(=)		1332	G=0.4527, A=0.5473		Present				-	34	NM_017617.3	c.6555C>T	synonymous	-0.09				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,Laminin EGF-like (Domains III and V),NOTCH protein	rs2229974		0.305 (ref)	0.4467	0.3639	0.4187	YES	Golgi apparatus,Golgi lumen,MAML1-RBP-Jkappa- ICN1 complex,Notch receptor processing,Notch signaling pathway,acrosomal vesicle,anagen,aortic valve morphogenesis,axonogenesis,branching morphogenesis of a tube,calcium ion binding,cell differentiation in spinal cord,cell fate specification,chromatin DNA binding,compartment pattern specification,core promoter binding,cytoplasm,cytosol,determination of left/right symmetry,embryo development,embryonic hindlimb morphogenesis,endoderm development,endoplasmic reticulum lumen,extracellular region,forebrain development,foregut morphogenesis,gene expression,hair follicle morphogenesis,heart development,immune response,in utero embryonic development,integral to membrane,liver development,lung development,negative regulation of BMP signaling pathway,negative regulation of apoptotic process,negative regulation of calcium ion-dependent exocytosis,negative regulation of cell death,negative regulation of cell-substrate adhesion,negative regulation of glial cell proliferation,negative regulation of myoblast differentiation,negative regulation of oligodendrocyte differentiation,negative regulation of osteoblast differentiation,negative regulation of photoreceptor cell differentiation,negative regulation of pro-B cell differentiation,negative regulation of stem cell differentiation,negative regulation of transcription from RNA polymerase II promoter,negative regulation of transcription, DNA-dependent,neural tube development,neuron fate commitment,neuronal stem cell maintenance,nucleoplasm,nucleus,organ regeneration,plasma membrane,positive regulation of BMP signaling pathway,positive regulation of JAK-STAT cascade,positive regulation of apoptotic process,positive regulation of astrocyte differentiation,positive regulation of cell proliferation,positive regulation of endothelial cell differentiation,positive regulation of epithelial cell proliferation,positive regulation of epithelial to mesenchymal transition,positive regulation of keratinocyte differentiation,positive regulation of neuroblast proliferation,positive regulation of transcription of Notch receptor target,positive regulation of transcription, DNA-dependent,prostate gland epithelium morphogenesis,protein binding,receptor activity,regulation of cardioblast proliferation,regulation of developmental process,regulation of epithelial cell proliferation involved in prostate gland development,regulation of neurogenesis,regulation of somitogenesis,regulation of transcription, DNA-dependent,response to corticosteroid stimulus,response to lipopolysaccharide,secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,somatic stem cell division,spermatogenesis,sprouting angiogenesis,tissue regeneration			0.00001	7202.78	G=603, A=729		G=362/241, A=460/269	1	
chr9:139397707	G/A	G	SNV		NOTCH1	exonic	1								53.15	p.(=)		1601	G=0.4685, A=0.5315		Present				-	27	NM_017617.3	c.5094C>T	synonymous	-0.82				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,Laminin EGF-like (Domains III and V),NOTCH protein	rs10521		0.417 (ref)	0.3534	0.4829	0.408	YES	Golgi apparatus,Golgi lumen,MAML1-RBP-Jkappa- ICN1 complex,Notch receptor processing,Notch signaling pathway,acrosomal vesicle,anagen,aortic valve morphogenesis,axonogenesis,branching morphogenesis of a tube,calcium ion binding,cell differentiation in spinal cord,cell fate specification,chromatin DNA binding,compartment pattern specification,core promoter binding,cytoplasm,cytosol,determination of left/right symmetry,embryo development,embryonic hindlimb morphogenesis,endoderm development,endoplasmic reticulum lumen,extracellular region,forebrain development,foregut morphogenesis,gene expression,hair follicle morphogenesis,heart development,immune response,in utero embryonic development,integral to membrane,liver development,lung development,negative regulation of BMP signaling pathway,negative regulation of apoptotic process,negative regulation of calcium ion-dependent exocytosis,negative regulation of cell death,negative regulation of cell-substrate adhesion,negative regulation of glial cell proliferation,negative regulation of myoblast differentiation,negative regulation of oligodendrocyte differentiation,negative regulation of osteoblast differentiation,negative regulation of photoreceptor cell differentiation,negative regulation of pro-B cell differentiation,negative regulation of stem cell differentiation,negative regulation of transcription from RNA polymerase II promoter,negative regulation of transcription, DNA-dependent,neural tube development,neuron fate commitment,neuronal stem cell maintenance,nucleoplasm,nucleus,organ regeneration,plasma membrane,positive regulation of BMP signaling pathway,positive regulation of JAK-STAT cascade,positive regulation of apoptotic process,positive regulation of astrocyte differentiation,positive regulation of cell proliferation,positive regulation of endothelial cell differentiation,positive regulation of epithelial cell proliferation,positive regulation of epithelial to mesenchymal transition,positive regulation of keratinocyte differentiation,positive regulation of neuroblast proliferation,positive regulation of transcription of Notch receptor target,positive regulation of transcription, DNA-dependent,prostate gland epithelium morphogenesis,protein binding,receptor activity,regulation of cardioblast proliferation,regulation of developmental process,regulation of epithelial cell proliferation involved in prostate gland development,regulation of neurogenesis,regulation of somitogenesis,regulation of transcription, DNA-dependent,response to corticosteroid stimulus,response to lipopolysaccharide,secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,somatic stem cell division,spermatogenesis,sprouting angiogenesis,tissue regeneration			0.00001	8260.36	G=750, A=851		G=456/294, A=518/333	1	
chr9:139413908	C/T	C	SNV		MIR4673,NOTCH1	exonic, downstream	1								43.01	p.(=)		1616	C=0.5699, T=0.4301		Present				-	5	NM_017617.3, NR_039820.1	c.852G>A	synonymous	-2.83				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,Laminin EGF-like (Domains III and V),NOTCH protein	rs2229975		0.101	0.1355	0.1031	0.1251	YES	Golgi apparatus,Golgi lumen,MAML1-RBP-Jkappa- ICN1 complex,Notch receptor processing,Notch signaling pathway,acrosomal vesicle,anagen,aortic valve morphogenesis,axonogenesis,branching morphogenesis of a tube,calcium ion binding,cell differentiation in spinal cord,cell fate specification,chromatin DNA binding,compartment pattern specification,core promoter binding,cytoplasm,cytosol,determination of left/right symmetry,embryo development,embryonic hindlimb morphogenesis,endoderm development,endoplasmic reticulum lumen,extracellular region,forebrain development,foregut morphogenesis,gene expression,hair follicle morphogenesis,heart development,immune response,in utero embryonic development,integral to membrane,liver development,lung development,negative regulation of BMP signaling pathway,negative regulation of apoptotic process,negative regulation of calcium ion-dependent exocytosis,negative regulation of cell death,negative regulation of cell-substrate adhesion,negative regulation of glial cell proliferation,negative regulation of myoblast differentiation,negative regulation of oligodendrocyte differentiation,negative regulation of osteoblast differentiation,negative regulation of photoreceptor cell differentiation,negative regulation of pro-B cell differentiation,negative regulation of stem cell differentiation,negative regulation of transcription from RNA polymerase II promoter,negative regulation of transcription, DNA-dependent,neural tube development,neuron fate commitment,neuronal stem cell maintenance,nucleoplasm,nucleus,organ regeneration,plasma membrane,positive regulation of BMP signaling pathway,positive regulation of JAK-STAT cascade,positive regulation of apoptotic process,positive regulation of astrocyte differentiation,positive regulation of cell proliferation,positive regulation of endothelial cell differentiation,positive regulation of epithelial cell proliferation,positive regulation of epithelial to mesenchymal transition,positive regulation of keratinocyte differentiation,positive regulation of neuroblast proliferation,positive regulation of transcription of Notch receptor target,positive regulation of transcription, DNA-dependent,prostate gland epithelium morphogenesis,protein binding,receptor activity,regulation of cardioblast proliferation,regulation of developmental process,regulation of epithelial cell proliferation involved in prostate gland development,regulation of neurogenesis,regulation of somitogenesis,regulation of transcription, DNA-dependent,response to corticosteroid stimulus,response to lipopolysaccharide,secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,somatic stem cell division,spermatogenesis,sprouting angiogenesis,tissue regeneration			0.00001	5928.96	C=921, T=695		C=427/494, T=327/368	1	
chr9:139418260	A/G	A	SNV		NOTCH1	exonic	1								42.30	p.(=)		1345	A=0.577, G=0.423		Present				-	3	NM_017617.3	c.312T>C	synonymous	-1.16				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,Laminin EGF-like (Domains III and V),NOTCH protein	rs4489420		0.293 (ref)	0.4711	0.1191	0.3913	YES	Golgi apparatus,Golgi lumen,MAML1-RBP-Jkappa- ICN1 complex,Notch receptor processing,Notch signaling pathway,acrosomal vesicle,anagen,aortic valve morphogenesis,axonogenesis,branching morphogenesis of a tube,calcium ion binding,cell differentiation in spinal cord,cell fate specification,chromatin DNA binding,compartment pattern specification,core promoter binding,cytoplasm,cytosol,determination of left/right symmetry,embryo development,embryonic hindlimb morphogenesis,endoderm development,endoplasmic reticulum lumen,extracellular region,forebrain development,foregut morphogenesis,gene expression,hair follicle morphogenesis,heart development,immune response,in utero embryonic development,integral to membrane,liver development,lung development,negative regulation of BMP signaling pathway,negative regulation of apoptotic process,negative regulation of calcium ion-dependent exocytosis,negative regulation of cell death,negative regulation of cell-substrate adhesion,negative regulation of glial cell proliferation,negative regulation of myoblast differentiation,negative regulation of oligodendrocyte differentiation,negative regulation of osteoblast differentiation,negative regulation of photoreceptor cell differentiation,negative regulation of pro-B cell differentiation,negative regulation of stem cell differentiation,negative regulation of transcription from RNA polymerase II promoter,negative regulation of transcription, DNA-dependent,neural tube development,neuron fate commitment,neuronal stem cell maintenance,nucleoplasm,nucleus,organ regeneration,plasma membrane,positive regulation of BMP signaling pathway,positive regulation of JAK-STAT cascade,positive regulation of apoptotic process,positive regulation of astrocyte differentiation,positive regulation of cell proliferation,positive regulation of endothelial cell differentiation,positive regulation of epithelial cell proliferation,positive regulation of epithelial to mesenchymal transition,positive regulation of keratinocyte differentiation,positive regulation of neuroblast proliferation,positive regulation of transcription of Notch receptor target,positive regulation of transcription, DNA-dependent,prostate gland epithelium morphogenesis,protein binding,receptor activity,regulation of cardioblast proliferation,regulation of developmental process,regulation of epithelial cell proliferation involved in prostate gland development,regulation of neurogenesis,regulation of somitogenesis,regulation of transcription, DNA-dependent,response to corticosteroid stimulus,response to lipopolysaccharide,secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,somatic stem cell division,spermatogenesis,sprouting angiogenesis,tissue regeneration			0.00001	4820.17	A=776, G=569		A=408/368, G=315/254	1	
chr10:43613843	T/T	G	SNV		RET	exonic	1								100.00	p.(=)		796	G=0.0, T=1.0		Present				+	13	NM_020975.4	c.2307G>T	synonymous	1.34				Cadherin domain,Protein kinase domain,Protein tyrosine kinase	rs1800861		0.277 (ref)	0.2347	0.1246	0.1974	YES	ATP binding,MAPKKK cascade,calcium ion binding,cellular response to retinoic acid,embryonic epithelial tube formation,endosome membrane,enteric nervous system development,homophilic cell adhesion,induction of apoptosis,integral to membrane,integral to plasma membrane,membrane,membrane protein proteolysis,nervous system development,neural crest cell migration,neuron maturation,nucleotide binding,positive regulation of cell adhesion mediated by integrin,positive regulation of cell migration,positive regulation of metanephric glomerulus development,positive regulation of neuron projection development,positive regulation of transcription, DNA-dependent,posterior midgut development,protein binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of cell adhesion,response to pain,signal transduction,transmembrane receptor protein tyrosine kinase activity,ureteric bud development	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo3,4-DPyrimidin-4-Ylamine,4-BROMO-2-FLUORO-N-(4E)-6-METHOXY-7-(1-METHYLPIPERIDIN-4-YL)METHOXYQUINAZOLIN-4(1H)-YLIDENEANILINE,Imatinib	untested	0.00001	11766.4	G=0, T=796		G=0/0, T=390/406	1	
chr10:123298158	T/C	T	SNV		FGFR2	exonic	1								52.86	p.(=)		1996	T=0.4714, C=0.5286		Present				-	6	NM_000141.4	c.696A>G	synonymous	0.96				Immunoglobulin I-set domain,Immunoglobulin V-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs1047100		0.176 (ref)	0.2236	0.2522	0.2333	YES	ATP binding,Golgi apparatus,angiogenesis,apoptotic process,axonogenesis,bone development,bone mineralization,bone morphogenesis,branch elongation involved in salivary gland morphogenesis,branching involved in embryonic placenta morphogenesis,branching involved in prostate gland morphogenesis,branching involved in salivary gland morphogenesis,branching morphogenesis of a nerve,bud elongation involved in lung branching,cell cortex,cell fate commitment,cell surface,cell-cell signaling,cytoplasm,cytoplasmic membrane-bounded vesicle,digestive tract development,embryonic digestive tract morphogenesis,embryonic organ development,embryonic organ morphogenesis,embryonic pattern specification,epidermis morphogenesis,epithelial cell differentiation,epithelial cell proliferation involved in salivary gland morphogenesis,excitatory synapse,extracellular matrix,extracellular region,fibroblast growth factor binding,fibroblast growth factor receptor signaling pathway,fibroblast growth factor receptor signaling pathway involved in hemopoiesis,fibroblast growth factor receptor signaling pathway involved in mammary gland specification,fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow,fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development,fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow,fibroblast growth factor-activated receptor activity,gland morphogenesis,hair follicle morphogenesis,heparin binding,in utero embryonic development,inner ear morphogenesis,insulin receptor signaling pathway,integral to membrane,integral to plasma membrane,lacrimal gland development,lateral sprouting from an epithelium,limb bud formation,lung alveolus development,lung development,lung lobe morphogenesis,lung-associated mesenchyme development,mammary gland bud formation,membrane,membranous septum morphogenesis,mesenchymal cell differentiation,mesenchymal cell differentiation involved in lung development,mesenchymal cell proliferation involved in lung development,midbrain development,morphogenesis of embryonic epithelium,multicellular organism growth,negative regulation of transcription from RNA polymerase II promoter,nucleotide binding,nucleus,odontogenesis,orbitofrontal cortex development,organ growth,organ morphogenesis,otic vesicle formation,outflow tract septum morphogenesis,peptidyl-tyrosine phosphorylation,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of MAPKKK cascade,positive regulation of Wnt receptor signaling pathway,positive regulation of canonical Wnt receptor signaling pathway,positive regulation of cardiac muscle cell proliferation,positive regulation of cell cycle,positive regulation of cell division,positive regulation of cell proliferation,positive regulation of epithelial cell proliferation,positive regulation of epithelial cell proliferation involved in lung morphogenesis,positive regulation of mesenchymal cell proliferation,positive regulation of phospholipase activity,positive regulation of transcription from RNA polymerase II promoter,post-embryonic development,prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,prostate epithelial cord elongation,prostate gland morphogenesis,protein autophosphorylation,protein binding,protein homodimerization activity,protein tyrosine kinase activity,pyramidal neuron development,receptor activity,regulation of ERK1 and ERK2 cascade,regulation of branching involved in prostate gland morphogenesis,regulation of cell fate commitment,regulation of fibroblast growth factor receptor signaling pathway,regulation of morphogenesis of a branching structure,regulation of multicellular organism growth,regulation of osteoblast differentiation,regulation of osteoblast proliferation,regulation of smooth muscle cell differentiation,regulation of smoothened signaling pathway,reproductive structure development,skeletal system morphogenesis,squamous basal epithelial stem cell differentiation involved in prostate gland acinus development,ureteric bud development,ventricular cardiac muscle tissue morphogenesis,ventricular zone neuroblast division	4-4-(1-Amino-1-Methylethyl)Phenyl-5-Chloro-N-4-(2-Morpholin-4-Ylethyl)PhenylPyrimidin-2-Amine,Palifermin,SU4984,Thalidomide		0.00001	10244.3	T=941, C=1055		T=487/454, C=585/470	1	
chr11:108183167	G/G	A	SNV		ATM	exonic	1								100.00	p.Asn1983Ser		1381	A=0.0, G=1.0		Present				+	40	NM_000051.3	c.5948A>G	missense	-0.19	1.0	46.0	0.0	FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase	rs659243		0.0 (ref)					1-phosphatidylinositol-3-kinase activity,ATP binding,DNA binding,DNA damage induced protein phosphorylation,DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,DNA damage response, signal transduction resulting in induction of apoptosis,DNA repair,DNA-dependent protein kinase activity,G2/M transition DNA damage checkpoint,brain development,cell cycle arrest,cell cycle checkpoint,cell death,cellular response to gamma radiation,chromosome, telomeric region,cytoplasm,cytoplasmic membrane-bounded vesicle,double-strand break repair,double-strand break repair via homologous recombination,female gamete generation,heart development,histone mRNA catabolic process,histone serine kinase activity,lipoprotein catabolic process,mitotic cell cycle spindle assembly checkpoint,negative regulation of B cell proliferation,negative regulation of apoptotic process,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,positive regulation of apoptotic process,positive regulation of neuron apoptosis,pre-B cell allelic exclusion,protein N-terminus binding,protein autophosphorylation,protein binding,protein complex binding,protein dimerization activity,protein serine/threonine kinase activity,reciprocal meiotic recombination,regulation of cell cycle,replicative senescence,response to DNA damage stimulus,response to hypoxia,response to ionizing radiation,signal transduction,somitogenesis,spindle			0.00001	20883.2	A=0, G=1381		A=0/0, G=815/566	2	
chr11:125525195	G/G	A	SNV		CHEK1	exonic	1								100.00	p.Ile471Val		1994	A=0.0, G=1.0		Present				+	13	NM_001274.5	c.1411A>G	missense	0.45	1.0	29.0	0.0	Protein kinase domain,Protein tyrosine kinase	rs506504		0.017 (ref)	0.0363	0.0064	0.0262	YES	ATP binding,DNA damage checkpoint,DNA damage induced protein phosphorylation,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,G2/M transition of mitotic cell cycle,cell cycle,cell cycle checkpoint,cellular response to caffeine,cellular response to mechanical stimulus,cellular response to organic substance,centrosome,chromatin,chromatin-mediated maintenance of transcription,chromosome, telomeric region,condensed nuclear chromosome,cytoplasm,cytoskeleton,histone H3-T11 phosphorylation,histone kinase activity (H3-T11 specific),negative regulation of mitosis,nucleoplasm,nucleotide binding,nucleus,peptidyl-threonine phosphorylation,protein binding,protein serine/threonine kinase activity,regulation of S phase,regulation of double-strand break repair via homologous recombination,regulation of histone H3-K9 acetylation,regulation of mitotic centrosome separation,regulation of transcription from RNA polymerase II promoter in response to UV-induced DNA damage,replication fork,replicative senescence,response to DNA damage stimulus	(2R)-1-(5,6-DIPHENYL-7H-PYRROLO2,3-DPYRIMIDIN-4-YL)AMINOPROPAN-2-OL,(2R)-3-{(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO2,3-DPYRIMIDIN-4-YLIDENEAMINO}PROPANE-1,2-DIOL,(2S)-1-AMINO-3-(5-NITROQUINOLIN-8-YL)AMINOPROPAN-2-OL,(3-ENDO)-8-METHYL-8-AZABICYCLO3.2.1OCT-3-YL 1H-PYRROLO2,3-BPYRIDINE-3-CARBOXYLATE,(3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE,(5,6-DIPHENYL-FURO2,3-DPYRIMIDIN-4-YLAMINO)-ACETIC,(5-{3-5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL,1-(2S)-4-(5-BROMO-1H-PYRAZOLO3,4-BPYRIDIN-4-YL)MORPHOLIN-2-YLMETHANAMINE,1-(2S)-4-(5-phenyl-1H-pyrazolo3,4-bpyridin-4-yl)morpholin-2-ylmethanamine,1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA,1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-2-(DIMETHYLAMINO)-1-METHYLETHOXYPYRAZIN-2-YL}UREA,18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE,2,2'-{9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYLBIS(OXY)}DIACETIC ACID,2-(5,6-DIPHENYLFURO2,3-DPYRIMIDIN-4-YL)AMINOETHANOL,2-(cyclohexylamino)benzoic acid,2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol,2-5,6-BIS-(4-METHOXY-PHENYL)-FURO2,3-DPYRIMIDIN-4-YLAMINO-ETHANOL,3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE,3-(5-{4-(AMINOMETHYL)PIPERIDIN-1-YLMETHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE,3-(5-{4-(AMINOMETHYL)PIPERIDIN-1-YLMETHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE,3-AMINO-3-BENZYL-4.3.0BICYCLO-1,6-DIAZANONAN-2-ONE,4-(3S)-1-AZABICYCLO2.2.2OCT-3-YLAMINO-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE,4-(6-{(4-METHYLCYCLOHEXYL)AMINOMETHYL}-1,4-DIHYDROINDENO1,2-CPYRAZOL-3-YL)BENZOIC ACID,4-3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL-2-METHOXYPHENOL,4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl(phenyl)methanone,5,6,7,8-TETRAHYDRO1BENZOTHIENO2,3-DPYRIMIDIN-4(3H)-ONE,5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO4,3-CQUINOLIN-4-ONE,6-MORPHOLIN-4-YL-9H-PURINE,N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-1,3THIAZOLO5,4-CAZEPIN-2-YL)ACETAMIDE,N-(5,6-DIPHENYLFURO2,3-DPYRIMIDIN-4-YL)GLYCINE,N-{5-4-(4-METHYLPIPERAZIN-1-YL)PHENYL-1H-PYRROLO2,3-BPYRIDIN-3-YL}NICOTINAMIDE,REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO1,2,3-FG:3',2',1'-KLPYRROLO3,4-I1,6BENZODIAZOCINE-1,3(2H)-DIONE		0.00001	30230.2	A=0, G=1994		A=0/0, G=922/1072	1	
chr12:25368462	T/T	C	SNV		KRAS	exonic	1								100.00	p.(=)		1988	C=0.0, T=1.0		Present				-	5	NM_033360.3	c.483G>A	synonymous	1.06				Miro-like protein,Ras family	rs4362222		0.0 (ref)	0.0	0.0043	0.0015		GDP binding,GMP binding,GTP binding,GTPase activity,LRR domain binding,MAPKKK cascade,Ral guanyl-nucleotide exchange factor activity,Ras protein signal transduction,activation of MAPKK activity,axon guidance,blood coagulation,cytokine-mediated signaling pathway,epidermal growth factor receptor signaling pathway,insulin receptor signaling pathway,leukocyte migration,membrane raft,mitochondrion,nerve growth factor receptor signaling pathway,nucleotide binding,plasma membrane,positive regulation of MAP kinase activity,positive regulation of NF-kappaB transcription factor activity,positive regulation of nitric-oxide synthase activity,protein binding,response to glucocorticoid stimulus,response to mineralocorticoid stimulus,signal transduction,small GTPase mediated signal transduction,social behavior	(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL-PHOSPHONIC ACID,FARNESYL,FARNESYL DIPHOSPHATE		0.00001	30135.1	C=0, T=1988		C=0/0, T=986/1002	3	
chr12:25398284	CC/AC	CC	SNV		KRAS	exonic	1	Hotspot	Gain-of-function			HS	COSM520;COSM522;COSM521;COSM512;COSM514;COSM34144;COSM25081;COSM13643		AA=0.00, AC=35.99, AG=0.00, AT=0.00, GC=0.00, TA=0.00, TC=0.00, TT=0.00	p.Gly12Val		1995	CC=0.6401, AA=0.0, AC=0.3599, AG=0.0, AT=0.0, GC=0.0, TA=0.0, TC=0.0, TT=0.0		Present				-	2	NM_033360.3	c.35G>T	missense	2.67,2.67	0.01	109.0	0.999	Miro-like protein,Ras family	rs121913529,rs121913530							GDP binding,GMP binding,GTP binding,GTPase activity,LRR domain binding,MAPKKK cascade,Ral guanyl-nucleotide exchange factor activity,Ras protein signal transduction,activation of MAPKK activity,axon guidance,blood coagulation,cytokine-mediated signaling pathway,epidermal growth factor receptor signaling pathway,insulin receptor signaling pathway,leukocyte migration,membrane raft,mitochondrion,nerve growth factor receptor signaling pathway,nucleotide binding,plasma membrane,positive regulation of MAP kinase activity,positive regulation of NF-kappaB transcription factor activity,positive regulation of nitric-oxide synthase activity,protein binding,response to glucocorticoid stimulus,response to mineralocorticoid stimulus,signal transduction,small GTPase mediated signal transduction,social behavior	(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL-PHOSPHONIC ACID,FARNESYL,FARNESYL DIPHOSPHATE	other	0.00001	5027.37	CC=1277, AA=0, AC=718, AG=0, AT=0, GC=0, TA=0, TC=0, TT=0		CC=680/597, AA=0/0, AC=391/327, AG=0/0, AT=0/0, GC=0/0, TA=0/0, TC=0/0, TT=0/0	2,2,2,2,2,2,2,2	
chr12:56360876	G/A	G	SNV		CDK2	exonic	1								57.99	p.(=)		1133	G=0.4201, A=0.5799		Present				+	1	NM_001798.3	c.84G>A	synonymous	0.08				Protein kinase domain,Protein tyrosine kinase	rs2069398		0.101 (ref)	0.0773	0.2783	0.1454	YES	ATP binding,Cajal body,DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,DNA repair,DNA replication,G1/S transition of mitotic cell cycle,G2 phase of mitotic cell cycle,G2/M transition of mitotic cell cycle,M/G1 transition of mitotic cell cycle,Ras protein signal transduction,S phase of mitotic cell cycle,X chromosome,Y chromosome,anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process,blood coagulation,cell cycle,cell cycle checkpoint,cell division,cellular response to nitric oxide,centrosome,centrosome duplication,chromosome, telomeric region,condensed chromosome,cyclin binding,cyclin-dependent protein kinase activity,cyclin-dependent protein kinase holoenzyme complex,cytoplasm,cytoskeleton,cytosol,endosome,histone kinase activity,histone phosphorylation,kinase activity,meiosis,metal ion binding,mitosis,mitotic cell cycle,mitotic cell cycle G1/S transition DNA damage checkpoint,nucleoplasm,nucleotide binding,nucleus,phosphorylation,positive regulation of cell proliferation,positive regulation of transcription, DNA-dependent,potassium ion transport,protein binding,protein kinase activity,protein phosphorylation,regulation of DNA replication,regulation of gene silencing,regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle,transcription factor complex,traversing start control point of mitotic cell cycle	(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO15.6.2.16,9.1,12,15.0,2,7.0,21,25HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE,(2R)-1-(DIMETHYLAMINO)-3-{4-(6-{2-FLUORO-5-(TRIFLUOROMETHYL)PHENYLAMINO}PYRIMIDIN-4-YL)AMINOPHENOXY}PROPAN-2-OL,(2R)-1-4-({4-(2,5-DICHLOROPHENYL)AMINOPYRIMIDIN-2-YL}AMINO)PHENOXY-3-(DIMETHYLAMINO)PROPAN-2-OL,(2R)-1-4-({6-(2,6-DIFLUOROPHENYL)AMINOPYRIMIDIN-4-YL}AMINO)PHENOXY-3-(DIMETHYLAMINO)PROPAN-2-OL,(2R)-1-{4-(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINOPHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL,(2R)-2-({9-(1-methylethyl)-6-(4-pyridin-2-ylbenzyl)amino-9H-purin-2-yl}amino)butan-1-ol,(2R)-2-{4-(benzylamino)-8-(1-methylethyl)pyrazolo1,5-a1,3,5triazin-2-ylamino}butan-1-ol,(2S)-1-4-({4-(2,5-DICHLOROPHENYL)AMINOPYRIMIDIN-2-YL}AMINO)PHENOXY-3-(DIMETHYLAMINO)PROPAN-2-OL,(2S)-1-4-({6-(2,6-DIFLUOROPHENYL)AMINOPYRIMIDIN-4-YL}AMINO)PHENOXY-3-(DIMETHYLAMINO)PROPAN-2-OL,(2S)-1-{4-(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINOPHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL,(2S)-N-(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE-2-4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYLPROPANAMIDE,(2Z)-5'-BROMO-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE AMMONIATE,(2e,3s)-3-Hydroxy-5'-(4-Hydroxypiperidin-1-Yl)Sulfonyl-3-Methyl-1,3-Dihydro-2,3'-Biindol-2'(1'h)-One,(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-1benzothieno3,2-e1,4diazepin-5-one,(4-AMINO-2-{1-(METHYLSULFONYL)PIPERIDIN-4-YLAMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE,(4E)-N-(4-fluorophenyl)-4-(phenylcarbonyl)imino-4H-pyrazole-3-carboxamide,(5-Chloropyrazolo1,5-aPyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine,(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo1,5-apyrimidin-3-yl)methanol,(5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO1,5-APYRIMIDIN-7-AMINE,1-(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy-3-Methyl-2-Butanol,1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID,1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO1,2-CPYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA,1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO2,1-AISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA,1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO1,2-APYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO}PHENOXY)PROPAN-2-OL,1-4-(AMINOSULFONYL)PHENYL-1,6-DIHYDROPYRAZOLO3,4-EINDAZOLE-3-CARBOXAMIDE,1-Amino-6-Cyclohex-3-Enylmethyloxypurine,1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo4,3-hquinazoline-3-carboxylic acid,2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE,2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO1,2-CPYRAZOL-5-YL)ACETAMIDE,2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE,2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo1,2-aPyridin-3-Yl-Phenyl-Methanone,2-Amino-6-Chloropyrazine,2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE,2-Trans-(4-Aminocyclohexyl)Amino-6-(Benzyl-Amino)-9-Cyclopentylpurine,2-{4-4-({4-2-methyl-1-(1-methylethyl)-1H-imidazol-5-ylpyrimidin-2-yl}amino)phenylpiperazin-1-yl}-2-oxoethanol,3-((3-bromo-5-o-tolylpyrazolo1,5-apyrimidin-7-ylamino)methyl)pyridine 1-oxide,3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE,3-({2-(4-{6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YLAMINO}PHENYL)SULFONYLETHYL}AMINO)PROPAN-1-OL,3-4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino-Phenol,3-Pyridin-4-Yl-2,4-Dihydro-Indeno1,2-.C.Pyrazole,3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo1,5-apyrimidin-7-amine,3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo1,5-apyrimidin-7-amine,3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo1,5-apyridin-7-amine,3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo1,2-apyridin-8-amine,3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo1,5-apyrimidin-7-amine,3-methyl-N-(pyridin-4-ylmethyl)imidazo1,2-apyrazin-8-amine,3-{(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINOMETHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE,3-{4-(AMINO(IMINO)METHYLAMINOSULFONYL)ANILINOMETHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE,4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene-1,3-Dihydro-Indol-2-One,4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl-(4-Trifluoromethyl-Phenyl)-Amine,4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine,4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine,4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl-(3-Nitro-Phenyl)-Amine,4-(4-Imidazo1,2-aPyridin-3-Ylpyrimidin-2-Yl)AminoBenzenesulfonamide,4-(4-methoxy-1H-pyrrolo2,3-bpyridin-3-yl)pyrimidin-2-amine,4-(4-propoxy-1H-pyrrolo2,3-bpyridin-3-yl)pyrimidin-2-amine,4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide,4-(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINOBENZENESULFONAMIDE,4-(6-Amino-4-Pyrimidinyl)AminoBenzenesulfonamide,4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE,4-(6-chloropyrazin-2-yl)aminobenzenesulfonamide,4-(7-OXO-7H-THIAZOLO5,4-EINDOL-8-YLMETHYL)-AMINO-N-PYRIDIN-2-YL-BENZENESULFONAMIDE,4-(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYLPHENOL,4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide,4-({5-(4-AMINOCYCLOHEXYL)AMINO1,2,4TRIAZOLO1,5-APYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE,4-3-Hydroxyanilino-6,7-Dimethoxyquinazoline,4-4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino-Phenol,4-5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo1,5-aPyrimidin-7-Ylamino-N,N-Dimethylbenzenesulfonamide,4-METHYL-5-{(2E)-2-(4-MORPHOLIN-4-YLPHENYL)IMINO-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE,4-{(2,6-dichlorophenyl)carbonylamino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide,4-{(2,6-difluorophenyl)carbonylamino}-N-(3S)-piperidin-3-yl-1H-pyrazole-3-carboxamide,4-{(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYLAMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE,4-{4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YLAMINO}-N-METHYLBENZENESULFONAMIDE,4-{4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YLAMINO}BENZAMIDE,4-{5-(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL-2-FURYL}BENZENESULFONAMIDE,4-{5-(CYCLOHEXYLAMINO)1,2,4TRIAZOLO1,5-APYRIMIDIN-7-YLAMINO}BENZENESULFONAMIDE,4-{5-(CYCLOHEXYLMETHOXY)1,2,4TRIAZOLO1,5-APYRIMIDIN-7-YLAMINO}BENZENESULFONAMIDE,4-{5-(CYCLOHEXYLOXY)1,2,4TRIAZOLO1,5-APYRIMIDIN-7-YLAMINO}BENZENESULFONAMIDE,4-{5-(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYLFURAN-2-YL}BENZENESULFONAMIDE,4-{5-(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL-2-FURYL}-N-METHYLBENZENESULFONAMIDE,4-{5-(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYLFURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE,4-{5-(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYLFURAN-2-YL}BENZENESULFONAMIDE,4-{5-(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYLFURAN-2-YL}BENZOIC ACID,5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo1,5-apyrimidin-7-amine,5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo1,5-apyrimidin-7-amine,5-(2-AMINOETHYL)AMINO-6-FLUORO-3-(1H-PYRROL-2-YL)BENZOCDINDOL-2(1H)-ONE,5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo1,5-apyrimidin-7-amine,5-(4-AMINOCYCLOHEXYL)AMINO-7-(PROPAN-2-YLAMINO)PYRAZOLO1,5-APYRIMIDINE-3-CARBONITRILE,5-5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL-3-{1-(2-CHLOROPHENYL)ETHYLOXY}-2-THIOPHENECARBOXAMIDE,5-chloro-7-(1-methylethyl)aminopyrazolo1,5-apyrimidine-3-carbonitrile,5-hydroxynaphthalene-1-sulfonamide,5-{(2-Amino-9h-Purin-6-Yl)OxyMethyl}-2-Pyrrolidinone,6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo1,2-apyrazin-8-amine,6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO3,4-DPYRIMIDIN-4(5H)-ONE,6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE,6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE,6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO12.3.1.1~3,7~NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE,6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE,6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE,6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE,6-O-Cyclohexylmethyl Guanine,9-amino-5-(2-aminopyrimidin-4-yl)pyrido3',2':4,5pyrrolo1,2-cpyrimidin-4-ol,Double Oxidized Cysteine,Flavopiridol,HYDROXY(OXO)(3-{(2Z)-4-3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYLPYRIMIDIN-2(5H)-YLIDENEAMINO}PHENYL)AMMONIUM,Hymenialdisine,Indirubin-3'-Monoxime,Lysine Nz-Carboxylic Acid,N'-(Pyrrolidino2,1-BIsoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea,N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo1,5-apyrimidin-7-amine,N-(2-METHOXYETHYL)-4-({4-2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YLPYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE,N-(3-CYCLOPROPYL-1H-PYRAZOL-5-YL)-2-(2-NAPHTHYL)ACETAMIDE,N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE,N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide,N-(4-{(3S)-3-(dimethylamino)pyrrolidin-1-ylcarbonyl}phenyl)-5-fluoro-4-2-methyl-1-(1-methylethyl)-1H-imidazol-5-ylpyrimidin-2-amine,N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide,N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE,N-3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YLBENZAMIDE,N-4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE,N-4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl-N'-Hydroxyimidoformamide,N-4-(2-Methylimidazo1,2-aPyridin-3-Yl)-2-PyrimidinylAcetamide,N-5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE,N-METHYL-4-{(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYLAMINO}BENZENESULFONAMIDE,N-METHYL-{4-2-(7-OXO-6,7-DIHYDRO-8H-1,3THIAZOLO5,4-EINDOL-8-YLIDENE)HYDRAZINOPHENYL}METHANESULFONAMIDE,N-cyclopropyl-4-pyrazolo1,5-bpyridazin-3-ylpyrimidin-2-amine,N-phenyl-1H-pyrazole-3-carboxamide,O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE,OLOMOUCINE II,Olomoucine,PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE,Purvalanol,SU9516,Staurosporine,TRIAZOLOPYRIMIDINE,{(2,6-difluorophenyl)carbonylamino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide		0.00001	6712.35	G=476, A=657		G=271/205, A=338/319	2	
chr12:133208979	T/C	T	SNV		POLE	exonic	1								56.83	p.(=)		1999	T=0.4317, C=0.5683		Present				-	45	NM_006231.3	c.6252A>G	synonymous	-2.14				DNA polymerase family B,Domain of unknown function (DUF1744)	rs5745022		0.307 (ref)	0.4157	0.2433	0.3573	YES	DNA binding,DNA repair,DNA replication,DNA synthesis involved in DNA repair,DNA-dependent DNA replication initiation,DNA-directed DNA polymerase activity,G1/S transition of mitotic cell cycle,M/G1 transition of mitotic cell cycle,S phase of mitotic cell cycle,base-excision repair, gap-filling,chromatin binding,in utero embryonic development,metal ion binding,mitotic cell cycle,nucleobase-containing compound metabolic process,nucleoplasm,nucleotide binding,nucleotide-excision repair,nucleotide-excision repair, DNA gap filling,nucleotidyltransferase activity,nucleus,telomere maintenance,telomere maintenance via recombination,telomere maintenance via semi-conservative replication,transcription-coupled nucleotide-excision repair,transferase activity,zinc ion binding	Cladribine		0.00001	11539.1	T=863, C=1136		T=344/519, C=499/637	1	
chr12:133219831	T/C	T	SNV		POLE	exonic	1								62.76	p.(=)		1391	T=0.3724, C=0.6276		Present				-	35	NM_006231.3	c.4530A>G	synonymous	-2.11				DNA polymerase family B,Domain of unknown function (DUF1744)	rs5744944		0.416 (ref)	0.4306	0.2985	0.4776	YES	DNA binding,DNA repair,DNA replication,DNA synthesis involved in DNA repair,DNA-dependent DNA replication initiation,DNA-directed DNA polymerase activity,G1/S transition of mitotic cell cycle,M/G1 transition of mitotic cell cycle,S phase of mitotic cell cycle,base-excision repair, gap-filling,chromatin binding,in utero embryonic development,metal ion binding,mitotic cell cycle,nucleobase-containing compound metabolic process,nucleoplasm,nucleotide binding,nucleotide-excision repair,nucleotide-excision repair, DNA gap filling,nucleotidyltransferase activity,nucleus,telomere maintenance,telomere maintenance via recombination,telomere maintenance via semi-conservative replication,transcription-coupled nucleotide-excision repair,transferase activity,zinc ion binding	Cladribine		0.00001	9410.77	T=518, C=873		T=177/341, C=311/562	1	
chr12:133235878	C/T	C	SNV		POLE	splicesite_3	1								5.61			107	C=0.9439, T=0.0561		Present				-	26	NM_006231.3			-0.74				DNA polymerase family B,Domain of unknown function (DUF1744)								DNA binding,DNA repair,DNA replication,DNA synthesis involved in DNA repair,DNA-dependent DNA replication initiation,DNA-directed DNA polymerase activity,G1/S transition of mitotic cell cycle,M/G1 transition of mitotic cell cycle,S phase of mitotic cell cycle,base-excision repair, gap-filling,chromatin binding,in utero embryonic development,metal ion binding,mitotic cell cycle,nucleobase-containing compound metabolic process,nucleoplasm,nucleotide binding,nucleotide-excision repair,nucleotide-excision repair, DNA gap filling,nucleotidyltransferase activity,nucleus,telomere maintenance,telomere maintenance via recombination,telomere maintenance via semi-conservative replication,transcription-coupled nucleotide-excision repair,transferase activity,zinc ion binding	Cladribine		0.04704	13.2754	C=101, T=6		C=58/43, T=3/3	1	
chr12:133236000	C/T	C	SNV		POLE	exonic	1								62.03	p.(=)		1999	C=0.3797, T=0.6203		Present				-	26	NM_006231.3	c.3156G>A	synonymous	-3.0				DNA polymerase family B,Domain of unknown function (DUF1744)	rs5744857		0.416 (ref)	0.4307	0.2985	0.4775	YES	DNA binding,DNA repair,DNA replication,DNA synthesis involved in DNA repair,DNA-dependent DNA replication initiation,DNA-directed DNA polymerase activity,G1/S transition of mitotic cell cycle,M/G1 transition of mitotic cell cycle,S phase of mitotic cell cycle,base-excision repair, gap-filling,chromatin binding,in utero embryonic development,metal ion binding,mitotic cell cycle,nucleobase-containing compound metabolic process,nucleoplasm,nucleotide binding,nucleotide-excision repair,nucleotide-excision repair, DNA gap filling,nucleotidyltransferase activity,nucleus,telomere maintenance,telomere maintenance via recombination,telomere maintenance via semi-conservative replication,transcription-coupled nucleotide-excision repair,transferase activity,zinc ion binding	Cladribine		0.00001	13289.2	C=759, T=1240		C=352/407, T=594/646	1	
chr13:28636084	A/A	G	SNV		FLT3	exonic	1								100.00	p.(=)		1998	G=0.0, A=1.0		Present				-	3	NM_004119.2	c.288C>T	synonymous	0.04				Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs7338903		0.041 (ref)	0.0105	0.0978	0.0401	YES	ATP binding,cell surface,cellular response to cytokine stimulus,cytokine receptor activity,cytokine-mediated signaling pathway,endoplasmic reticulum,endoplasmic reticulum lumen,hemopoiesis,integral to plasma membrane,lymphocyte differentiation,membrane,myeloid progenitor cell differentiation,negative regulation of B cell differentiation,negative regulation of cell proliferation,nucleotide binding,peptidyl-tyrosine phosphorylation,phosphatidylinositol 3-kinase binding,positive regulation of MAP kinase activity,positive regulation of MAPKKK cascade,positive regulation of cell proliferation,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of tyrosine phosphorylation of STAT protein,pro-B cell differentiation,pro-T cell differentiation,protein autophosphorylation,protein homodimerization activity,receptor activity,regulation of apoptotic process,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway,vascular endothelial growth factor receptor signaling pathway,vascular endothelial growth factor-activated receptor activity	Sorafenib,Sunitinib		0.00001	30466.6	G=0, A=1998		G=0/0, A=972/1026	1	
chr13:32899321		G	GENE_EXPRESSION		BRCA2								BRCA2.E5E6				21777				Present			2.4821e-08																						0.0					
chr13:32906729	A/C	A	SNV		BRCA2	exonic	1								21.36	p.Asn372His		1999	A=0.7864, C=0.2136		Present				+	10	NM_000059.3	c.1114A>C	missense	-0.15	0.15	68.0	0.023	BRCA2 repeat	rs144848		0.24 (ref)	0.2859	0.1289	0.2332	YES	BRCA2-MAGE-D1 complex,DNA binding,DNA recombination,DNA repair,H3 histone acetyltransferase activity,H4 histone acetyltransferase activity,cell cycle,cell cycle cytokinesis,centrosome,centrosome duplication,cytoplasm,double-strand break repair,double-strand break repair via homologous recombination,gamma-tubulin binding,histone H3 acetylation,histone H4 acetylation,histone acetyltransferase activity,homologous chromosome orientation involved in meiotic metaphase I plate congression,mammary gland development,multicellular organism growth,negative regulation of mammary gland epithelial cell proliferation,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,positive regulation of transcription, DNA-dependent,protease binding,protein binding,protein complex,regulation of S phase of mitotic cell cycle,response to estradiol stimulus,response to nutrient,secretory granule,single-stranded DNA binding,spermatogenesis		non-pathogenic,other	0.00001	2242.29	A=1572, C=427		A=687/885, C=190/237	3	
chr13:32913055	G/G	A	SNV		BRCA2	exonic	1								100.00	p.(=)		1998	A=0.0, G=1.0		Present				+	11	NM_000059.3	c.4563A>G	synonymous	0.6				BRCA2 repeat	rs206075		0.026 (ref)	6.0E-4	0.0704	0.0242	YES	BRCA2-MAGE-D1 complex,DNA binding,DNA recombination,DNA repair,H3 histone acetyltransferase activity,H4 histone acetyltransferase activity,cell cycle,cell cycle cytokinesis,centrosome,centrosome duplication,cytoplasm,double-strand break repair,double-strand break repair via homologous recombination,gamma-tubulin binding,histone H3 acetylation,histone H4 acetylation,histone acetyltransferase activity,homologous chromosome orientation involved in meiotic metaphase I plate congression,mammary gland development,multicellular organism growth,negative regulation of mammary gland epithelial cell proliferation,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,positive regulation of transcription, DNA-dependent,protease binding,protein binding,protein complex,regulation of S phase of mitotic cell cycle,response to estradiol stimulus,response to nutrient,secretory granule,single-stranded DNA binding,spermatogenesis			0.00001	30412.5	A=0, G=1998		A=0/0, G=1195/803	1	
chr13:32915005	C/C	G	SNV		BRCA2	exonic	1								100.00	p.(=)		1999	G=0.0, C=1.0		Present				+	11	NM_000059.3	c.6513G>C	synonymous	-1.1				BRCA2 repeat	rs206076		0.026 (ref)	6.0E-4	0.0713	0.0245	YES	BRCA2-MAGE-D1 complex,DNA binding,DNA recombination,DNA repair,H3 histone acetyltransferase activity,H4 histone acetyltransferase activity,cell cycle,cell cycle cytokinesis,centrosome,centrosome duplication,cytoplasm,double-strand break repair,double-strand break repair via homologous recombination,gamma-tubulin binding,histone H3 acetylation,histone H4 acetylation,histone acetyltransferase activity,homologous chromosome orientation involved in meiotic metaphase I plate congression,mammary gland development,multicellular organism growth,negative regulation of mammary gland epithelial cell proliferation,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,positive regulation of transcription, DNA-dependent,protease binding,protein binding,protein complex,regulation of S phase of mitotic cell cycle,response to estradiol stimulus,response to nutrient,secretory granule,single-stranded DNA binding,spermatogenesis			0.00001	30458.1	G=0, C=1999		G=0/0, C=1136/863	1	
chr13:32929387	C/C	T	SNV		BRCA2	exonic	1								100.00	p.Val2466Ala		1998	T=0.0, C=1.0		Present				+	14	NM_000059.3	c.7397T>C	missense	1.27	0.58	64.0	0.0	BRCA2 repeat	rs169547		0.022 (ref)	6.0E-4	0.0647	0.0223	YES	BRCA2-MAGE-D1 complex,DNA binding,DNA recombination,DNA repair,H3 histone acetyltransferase activity,H4 histone acetyltransferase activity,cell cycle,cell cycle cytokinesis,centrosome,centrosome duplication,cytoplasm,double-strand break repair,double-strand break repair via homologous recombination,gamma-tubulin binding,histone H3 acetylation,histone H4 acetylation,histone acetyltransferase activity,homologous chromosome orientation involved in meiotic metaphase I plate congression,mammary gland development,multicellular organism growth,negative regulation of mammary gland epithelial cell proliferation,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,positive regulation of transcription, DNA-dependent,protease binding,protein binding,protein complex,regulation of S phase of mitotic cell cycle,response to estradiol stimulus,response to nutrient,secretory granule,single-stranded DNA binding,spermatogenesis		untested	0.00001	30423.0	T=0, C=1998		T=0/0, C=912/1086	1	
chr13:48919335		G	GENE_EXPRESSION		RB1								RB1.E4E5				153				Present			1.7439e-10																						0.0					
chr13:49050979		G	GENE_EXPRESSION		RB1								RB1.E26E27				27				Present			3.0775e-11																						0.0					
chr14:105239894	C/T	C	SNV		AKT1	exonic	1								18.73	p.(=)		1201	C=0.8127, T=0.1873		Present				-	9	NM_001014431.1	c.726G>A	synonymous	2.2				PH domain,Protein kinase C terminal domain,Protein kinase domain,Protein tyrosine kinase	rs1130233		0.314 (ref)	0.2459	0.1151	0.2016	YES	ATP binding,G-protein coupled receptor signaling pathway,RNA metabolic process,T cell costimulation,activation of pro-apoptotic gene products,activation-induced cell death of T cells,anti-apoptosis,apoptotic process,blood coagulation,carbohydrate metabolic process,carbohydrate transport,cell differentiation,cell proliferation,cellular response to insulin stimulus,cytoplasm,cytosol,endocrine pancreas development,enzyme binding,fibroblast growth factor receptor signaling pathway,identical protein binding,induction of apoptosis by intracellular signals,insulin receptor signaling pathway,insulin-like growth factor receptor signaling pathway,intracellular signal transduction,kinase activity,mRNA metabolic process,mammary gland epithelial cell differentiation,membrane fraction,microtubule cytoskeleton,multicellular organismal development,negative regulation of apoptotic process,negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,negative regulation of fatty acid beta-oxidation,negative regulation of plasma membrane long-chain fatty acid transport,negative regulation of protein kinase activity,negative regulation of release of cytochrome c from mitochondria,nerve growth factor receptor signaling pathway,nervous system development,nitric oxide biosynthetic process,nitric oxide metabolic process,nitric-oxide synthase regulator activity,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,phosphatidylinositol-3,4,5-trisphosphate binding,phosphatidylinositol-3,4-bisphosphate binding,phosphatidylinositol-mediated signaling,phosphorylation,plasma membrane,platelet activation,positive regulation of anti-apoptosis,positive regulation of blood vessel endothelial cell migration,positive regulation of cell growth,positive regulation of cellular protein metabolic process,positive regulation of cyclin-dependent protein kinase activity involved in G1/S,positive regulation of establishment of protein localization in plasma membrane,positive regulation of fat cell differentiation,positive regulation of glucose import,positive regulation of glucose metabolic process,positive regulation of glycogen biosynthetic process,positive regulation of lipid biosynthetic process,positive regulation of nitric oxide biosynthetic process,positive regulation of nitric-oxide synthase activity,positive regulation of peptidyl-serine phosphorylation,positive regulation of protein phosphorylation,positive regulation of sequence-specific DNA binding transcription factor activity,protein autophosphorylation,protein binding,protein import into nucleus, translocation,protein kinase activity,protein modification process,protein phosphorylation,protein serine/threonine kinase activity,regulation of G1/S transition checkpoint,regulation of cell migration,regulation of glycogen biosynthetic process,regulation of neuron projection development,regulation of nitric-oxide synthase activity,regulation of translation,response to UV-A,response to fluid shear stress,response to heat,signal transduction,transport	5-(5-chloro-7H-pyrrolo2,3-dpyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo4,5-cpyridine,Adenosine triphosphate,Arsenic trioxide,Inositol 1,3,4,5-Tetrakisphosphate,N-2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl-7H-pyrrolo2,3-dpyrimidin-4-amine		0.00001	1064.82	C=976, T=225		C=521/455, T=120/105	1	
chr15:88576185	G/C	G	SNV		NTRK3	exonic	1								48.40	p.(=)		1692	G=0.516, C=0.484		Present				-	14	NM_001012338.2	c.1488C>G	synonymous	-2.01				Immunoglobulin I-set domain,Immunoglobulin domain,Leucine rich repeat N-terminal domain,Protein kinase domain,Protein tyrosine kinase	rs2229910		0.322 (ref)	0.3551	0.4048	0.3719	YES	ATP binding,Golgi membrane,cell differentiation,cellular response to retinoic acid,cochlea development,cytoplasm,integral to plasma membrane,mechanoreceptor differentiation,membrane fraction,modulation by virus of host transcription,multicellular organismal development,negative regulation of astrocyte differentiation,negative regulation of cell death,nervous system development,neuron fate specification,neuron migration,neurotrophin binding,nucleotide binding,plasma membrane,positive regulation of axon extension involved in regeneration,protein autophosphorylation,receptor activity,response to axon injury,response to corticosterone stimulus,response to ethanol,response to stress,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	7431.95	G=873, C=819		G=391/482, C=353/466	2	
chr15:89803950	C/T	C	SNV		FANCI	exonic	1								48.07	p.Pro55Leu		1999	C=0.5193, T=0.4807		Present				+	4	NM_001113378.1	c.164C>T	missense	2.62	0.0	98.0	1.0		rs62020347		0.032 (ref)	0.0678	0.0234	0.0528	YES	DNA repair,cell cycle,nucleoplasm,nucleus,plasma membrane,protein binding			0.00001	8818.52	C=1038, T=961		C=527/511, T=404/557	5	
chr15:89838236	A/A	G	SNV		FANCI	exonic	1								100.00	p.(=)		1992	G=0.0, A=1.0		Present				+	24	NM_001113378.1	c.2547G>A	synonymous	0.3					rs7183618		0.027 (ref)	0.0535	0.0087	0.0399	YES	DNA repair,cell cycle,nucleoplasm,nucleus,plasma membrane,protein binding			0.00001	30170.5	G=0, A=1992		G=0/0, A=857/1135	2	
chr16:2105400	C/T	C	SNV		TSC2	splicesite_5	1								25.68			1628	C=0.7432, T=0.2568		Present				+	6	NM_000548.3			0.12				Rap/ran-GAP,Tuberin	rs1800720		0.092 (ref)	0.0966	0.1906	0.1284	YES	14-3-3 protein binding,GTPase activator activity,Golgi apparatus,TSC1-TSC2 complex,acute-phase response,caveola,cell cycle arrest,cell projection organization,cytoplasm,cytoskeletal part,cytosol,dendrite,endocytosis,establishment of protein localization,fibroblast growth factor receptor signaling pathway,growth cone,heart development,insulin receptor signaling pathway,insulin-like growth factor receptor signaling pathway,intracellular,membrane,membrane fraction,microsome,negative regulation of MAP kinase activity,negative regulation of TOR signaling cascade,negative regulation of Wnt receptor signaling pathway,negative regulation of cell proliferation,negative regulation of cell size,negative regulation of epithelial cell proliferation,negative regulation of phosphatidylinositol 3-kinase cascade,negative regulation of protein kinase B signaling cascade,negative regulation of protein kinase activity,nerve growth factor receptor signaling pathway,neural tube closure,neuronal cell body,nucleus,perinuclear region of cytoplasm,phosphatase binding,phosphatidylinositol-mediated signaling,positive chemotaxis,positive regulation of GTPase activity,protein binding,protein heterodimerization activity,protein heterooligomerization,protein homodimerization activity,protein homooligomerization,protein import into nucleus,protein kinase B signaling cascade,protein localization,regulation of cell cycle,regulation of endocytosis,regulation of insulin receptor signaling pathway,regulation of small GTPase mediated signal transduction,response to hypoxia,signal transduction,vesicle-mediated transport		untested	0.00001	2526.74	C=1210, T=418		C=628/582, T=195/223	5	
chr16:3639139	G/G	A	SNV		SLX4	exonic	1								100.00	p.(=)		1297	A=0.0, G=1.0		Present				-	12	NM_032444.2	c.4500T>C	synonymous	0.83				BTB/POZ domain	rs3810812		0.306 (ref)	0.4923	0.1406	0.3734	YES	3'-flap endonuclease activity,5'-flap endonuclease activity,DNA double-strand break processing involved in repair via single-strand annealing,DNA recombination,DNA repair,ERCC4-ERCC1 complex,Holliday junction resolvase complex,Slx1-Slx4 complex,crossover junction endodeoxyribonuclease activity,double-strand break repair via homologous recombination,enzyme activator activity,nuclear chromatin,nuclear chromosome, telomeric region,nucleotide-excision repair,nucleus,positive regulation of catalytic activity,protein binding			0.00001	19569.2	A=0, G=1297		A=0/0, G=579/718	1	
chr16:3656482	C/T	C	SNV		SLX4	exonic	1								27.15	p.(=)		2000	C=0.7285, T=0.2715		Present				-	3	NM_032444.2	c.753G>A	synonymous	-3.47				BTB/POZ domain	rs8061528		0.25 (ref)	0.203	0.2501	0.2189	YES	3'-flap endonuclease activity,5'-flap endonuclease activity,DNA double-strand break processing involved in repair via single-strand annealing,DNA recombination,DNA repair,ERCC4-ERCC1 complex,Holliday junction resolvase complex,Slx1-Slx4 complex,crossover junction endodeoxyribonuclease activity,double-strand break repair via homologous recombination,enzyme activator activity,nuclear chromatin,nuclear chromosome, telomeric region,nucleotide-excision repair,nucleus,positive regulation of catalytic activity,protein binding			0.00001	3423.21	C=1457, T=543		C=695/762, T=256/287	4	
chr16:3777836	T/C	T	SNV		CREBBP	exonic	1								74.27	p.(=)		1998	T=0.2573, C=0.7427		Present				-	31	NM_004380.2	c.7212A>G	synonymous	2.16				Bromodomain,Domain of Unknown Function (DUF902),KIX domain,TAZ zinc finger,Zinc finger	rs55916120		0.013 (ref)	0.0256	0.005	0.0186	YES	MyoD binding,N-terminal peptidyl-lysine acetylation,RNA polymerase II activating transcription factor binding,RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in negative regulation of transcription,RNA polymerase II transcription coactivator activity,RNA polymerase II transcription factor binding,RNA polymerase II transcription factor binding transcription factor activity involved in negative regulation of transcription,SMAD binding,acetyltransferase activity,cell proliferation,cellular lipid metabolic process,core promoter proximal region sequence-specific DNA binding,cytoplasm,embryonic digit morphogenesis,gene expression,histone acetylation,histone acetyltransferase activity,histone acetyltransferase complex,homeostatic process,innate immune response,interspecies interaction between organisms,metal ion binding,negative regulation of transcription from RNA polymerase II promoter,nuclear body,nuclear chromatin,nucleoplasm,nucleus,p53 binding,peroxisome proliferator activated receptor binding,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,protein binding,protein complex assembly,regulation of S phase,regulation of smoothened signaling pathway,regulation of transcription, DNA-dependent,response to hypoxia,sequence-specific DNA binding transcription factor activity,signal transducer activity,signal transduction,transcription coactivator activity,transcription factor binding,transferase activity,zinc ion binding	9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE		0.00001	17796.4	T=514, C=1484		T=267/247, C=724/760	2	
chr16:89866043	T/C	T	SNV		FANCA	exonic	1								72.09	p.Thr266Ala		1999	T=0.2791, C=0.7209		Present				-	9	NM_000135.2	c.796A>G	missense	0.38	1.0	58.0	0.0	Fanconi anaemia group A protein	rs7190823		0.343 (ref)	0.3937	0.2743	0.494	YES	DNA repair,Fanconi anaemia nuclear complex,cytoplasm,female gonad development,male gonad development,male meiosis,nucleoplasm,nucleus,protein binding,protein complex assembly,regulation of cell proliferation			0.00001	16945.4	T=558, C=1441		T=242/316, C=594/847	1	
chr17:7574000	C/A	C	SNV		TP53	exonic	1	Deleterious	Loss-of-function						50.88	p.Glu343Ter		1590	C=0.4912, A=0.5088		Present				-	10	NM_000546.5	c.1027G>T	nonsense	0.03				P53 DNA-binding domain,P53 tetramerisation motif,P53 transactivation motif	rs375573770			0.0	2.0E-4	1.0E-4		ATP binding,B cell lineage commitment,DNA binding,DNA damage response, signal transduction by p53 class mediator,DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA strand annealing activity,DNA strand renaturation,ER overload response,MDM2 binding,PML body,RNA polymerase II transcription factor binding,Ras protein signal transduction,T cell differentiation in thymus,T cell lineage commitment,T cell proliferation involved in immune response,activation of caspase activity by cytochrome c,apoptotic process,base-excision repair,blood coagulation,cell aging,cell cycle arrest,cell cycle checkpoint,cell differentiation,cell proliferation,cellular protein localization,cellular response to UV,cellular response to drug,cellular response to glucose starvation,cellular response to hypoxia,cellular response to ionizing radiation,central nervous system development,chaperone binding,chromatin,chromatin assembly complex,chromatin binding,chromosome organization,copper ion binding,cytoplasm,cytosol,damaged DNA binding,determination of adult lifespan,double-strand break repair,embryo development ending in birth or egg hatching,endoplasmic reticulum,enzyme binding,gastrulation,histone acetyltransferase binding,histone deacetylase regulator activity,identical protein binding,in utero embryonic development,induction of apoptosis by intracellular signals,insoluble fraction,interspecies interaction between organisms,metal ion binding,mitochondrion,mitotic cell cycle G1/S transition DNA damage checkpoint,multicellular organism growth,multicellular organismal development,negative regulation of DNA replication,negative regulation of apoptotic process,negative regulation of cell growth,negative regulation of cell proliferation,negative regulation of fibroblast proliferation,negative regulation of helicase activity,negative regulation of neuroblast proliferation,negative regulation of transcription from RNA polymerase II promoter,negative regulation of transcription, DNA-dependent,negative regulation of transforming growth factor beta receptor signaling pathway,nuclear body,nuclear chromatin,nuclear matrix,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,oxidative stress-induced premature senescence,p53 binding,positive regulation of apoptotic process,positive regulation of cell aging,positive regulation of cell cycle arrest,positive regulation of histone deacetylation,positive regulation of neuron apoptosis,positive regulation of peptidyl-tyrosine phosphorylation,positive regulation of reactive oxygen species metabolic process,positive regulation of thymocyte apoptosis,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,protease binding,protein N-terminus binding,protein binding,protein complex,protein complex assembly,protein heterodimerization activity,protein import into nucleus, translocation,protein kinase binding,protein localization,protein phosphatase 2A binding,protein tetramerization,rRNA transcription,regulation of apoptotic process,regulation of cell cycle,regulation of mitochondrial membrane permeability,regulation of transcription, DNA-dependent,release of cytochrome c from mitochondria,replication fork,replicative senescence,response to DNA damage stimulus,response to X-ray,response to antibiotic,response to gamma radiation,sequence-specific DNA binding transcription factor activity,signal transduction by p53 class mediator resulting in induction of apoptosis,somitogenesis,transcription factor TFIID complex,transcription factor binding,transcription regulatory region DNA binding,ubiquitin protein ligase binding,zinc ion binding	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine		0.00001	7680.27	C=781, A=809		C=399/382, A=433/376	1	
chr17:7579472	G/C	G	SNV		TP53	exonic	1								95.55	p.Pro72Arg		1707	G=0.0445, C=0.9555		Present				-	4	NM_000546.5	c.215C>G	missense	1.36	0.6	103.0	0.083	P53 DNA-binding domain,P53 tetramerisation motif,P53 transactivation motif	rs1042522		0.398 (ref)	0.2548	0.4051	0.37	YES	ATP binding,B cell lineage commitment,DNA binding,DNA damage response, signal transduction by p53 class mediator,DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA strand annealing activity,DNA strand renaturation,ER overload response,MDM2 binding,PML body,RNA polymerase II transcription factor binding,Ras protein signal transduction,T cell differentiation in thymus,T cell lineage commitment,T cell proliferation involved in immune response,activation of caspase activity by cytochrome c,apoptotic process,base-excision repair,blood coagulation,cell aging,cell cycle arrest,cell cycle checkpoint,cell differentiation,cell proliferation,cellular protein localization,cellular response to UV,cellular response to drug,cellular response to glucose starvation,cellular response to hypoxia,cellular response to ionizing radiation,central nervous system development,chaperone binding,chromatin,chromatin assembly complex,chromatin binding,chromosome organization,copper ion binding,cytoplasm,cytosol,damaged DNA binding,determination of adult lifespan,double-strand break repair,embryo development ending in birth or egg hatching,endoplasmic reticulum,enzyme binding,gastrulation,histone acetyltransferase binding,histone deacetylase regulator activity,identical protein binding,in utero embryonic development,induction of apoptosis by intracellular signals,insoluble fraction,interspecies interaction between organisms,metal ion binding,mitochondrion,mitotic cell cycle G1/S transition DNA damage checkpoint,multicellular organism growth,multicellular organismal development,negative regulation of DNA replication,negative regulation of apoptotic process,negative regulation of cell growth,negative regulation of cell proliferation,negative regulation of fibroblast proliferation,negative regulation of helicase activity,negative regulation of neuroblast proliferation,negative regulation of transcription from RNA polymerase II promoter,negative regulation of transcription, DNA-dependent,negative regulation of transforming growth factor beta receptor signaling pathway,nuclear body,nuclear chromatin,nuclear matrix,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,oxidative stress-induced premature senescence,p53 binding,positive regulation of apoptotic process,positive regulation of cell aging,positive regulation of cell cycle arrest,positive regulation of histone deacetylation,positive regulation of neuron apoptosis,positive regulation of peptidyl-tyrosine phosphorylation,positive regulation of reactive oxygen species metabolic process,positive regulation of thymocyte apoptosis,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,protease binding,protein N-terminus binding,protein binding,protein complex,protein complex assembly,protein heterodimerization activity,protein import into nucleus, translocation,protein kinase binding,protein localization,protein phosphatase 2A binding,protein tetramerization,rRNA transcription,regulation of apoptotic process,regulation of cell cycle,regulation of mitochondrial membrane permeability,regulation of transcription, DNA-dependent,release of cytochrome c from mitochondria,replication fork,replicative senescence,response to DNA damage stimulus,response to X-ray,response to antibiotic,response to gamma radiation,sequence-specific DNA binding transcription factor activity,signal transduction by p53 class mediator resulting in induction of apoptosis,somitogenesis,transcription factor TFIID complex,transcription factor binding,transcription regulatory region DNA binding,ubiquitin protein ligase binding,zinc ion binding	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	non-pathogenic	0.00001	23544.3	G=76, C=1631		G=23/53, C=674/957	6	
chr17:29508775	A/A	G	SNV		NF1	exonic	1								100.00	p.(=)		1926	G=0.0, A=1.0		Present				+	7	NM_001042492.2	c.702G>A	synonymous	-3.81				GTPase-activator protein for Ras-like GTPase	rs1801052		0.45 (ref)	0.2899	0.3098	0.4256	YES	MAPKKK cascade,Ras GTPase activator activity,Ras protein signal transduction,Schwann cell development,actin cytoskeleton organization,adrenal gland development,artery morphogenesis,axon,brain development,camera-type eye morphogenesis,cell communication,cerebral cortex development,cognition,collagen fibril organization,cytoplasm,dendrite,extracellular matrix organization,forebrain astrocyte development,forebrain morphogenesis,heart development,intracellular,intrinsic to internal side of plasma membrane,liver development,metanephros development,myelination in peripheral nervous system,negative regulation of MAP kinase activity,negative regulation of MAPKKK cascade,negative regulation of Rac protein signal transduction,negative regulation of Ras protein signal transduction,negative regulation of angiogenesis,negative regulation of astrocyte differentiation,negative regulation of cell migration,negative regulation of endothelial cell proliferation,negative regulation of fibroblast proliferation,negative regulation of neuroblast proliferation,negative regulation of neurotransmitter secretion,negative regulation of oligodendrocyte differentiation,negative regulation of protein kinase activity,negative regulation of transcription factor import into nucleus,neural tube development,nucleus,osteoblast differentiation,peripheral nervous system development,phosphatidylinositol 3-kinase cascade,pigmentation,positive regulation of Ras GTPase activity,positive regulation of adenylate cyclase activity,positive regulation of apoptotic process,positive regulation of endothelial cell proliferation,positive regulation of neuron apoptosis,protein binding,regulation of Ras GTPase activity,regulation of angiogenesis,regulation of blood vessel endothelial cell migration,regulation of bone resorption,regulation of cell-matrix adhesion,regulation of glial cell differentiation,regulation of long-term neuronal synaptic plasticity,regulation of small GTPase mediated signal transduction,regulation of synaptic transmission, GABAergic,response to hypoxia,signal transduction,skeletal muscle tissue development,smooth muscle tissue development,spinal cord development,sympathetic nervous system development,visual learning,wound healing			0.00001	29211.8	G=0, A=1926		G=0/0, A=1311/615	1	
chr17:41215907		C	GENE_EXPRESSION		BRCA1								BRCA1-BRCA1.B15B18				43				Present			4.9011e-11																						0.0					
chr17:41223094	T/C	T	SNV		BRCA1	exonic	1								38.70	p.Ser1634Gly		2000	T=0.613, C=0.387		Present				-	16	NM_007300.3	c.4900A>G	missense	0.13	0.03	56.0	0.58	BRCA1 C Terminus (BRCT) domain,Zinc finger	rs1799966		0.327	0.3266	0.2426	0.2982	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		non-pathogenic	0.00001	6193.68	T=1226, C=774		T=650/576, C=393/381	1	
chr17:41234470	A/G	A	SNV		BRCA1	exonic	1								39.60	p.(=)		2000	A=0.604, G=0.396		Present				-	12	NM_007300.3	c.4308T>C	synonymous	0.13				BRCA1 C Terminus (BRCT) domain,Zinc finger	rs1060915		0.304 (ref)	0.326	0.1888	0.2796	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		untested	0.00001	6439.77	A=1208, G=792		A=585/623, G=401/391	2	
chr17:41244000	T/C	T	SNV		BRCA1	exonic	1								38.67	p.Lys1183Arg		1999	T=0.6133, C=0.3867		Present				-	10	NM_007300.3	c.3548A>G	missense	-0.44	1.0	26.0	0.0	BRCA1 C Terminus (BRCT) domain,Zinc finger	rs16942,rs80357956		0.324 (ref)	0.3244	0.2383	0.2952	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		non-pathogenic	0.00001	6191.0	T=1226, C=773		T=636/590, C=408/365	3	
chr17:41244435	T/C	T	SNV		BRCA1	exonic	1								42.22	p.Glu1038Gly		1999	T=0.5778, C=0.4222		Present				-	10	NM_007300.3	c.3113A>G	missense	0.11	0.02	98.0	0.158	BRCA1 C Terminus (BRCT) domain,Zinc finger	rs16941,rs80357920		0.303 (ref)	0.3255	0.1884	0.279	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		non-pathogenic	0.00001	7146.35	T=1155, C=844		T=563/592, C=424/420	2	
chr17:41244936	G/A	G	SNV		BRCA1	exonic	1								39.66	p.Pro871Leu		1997	G=0.6034, A=0.3966		Present				-	10	NM_007300.3	c.2612C>T	missense	0.94	1.0	98.0	0.0	BRCA1 C Terminus (BRCT) domain,Zinc finger	rs799917,rs80357962		0.483	0.3359	0.2	0.4932	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		non-pathogenic	0.00001	6445.44	G=1205, A=792		G=614/591, A=410/382	2	
chr17:41245237	A/G	A	SNV		BRCA1	exonic	1								40.10	p.(=)		2000	A=0.599, G=0.401		Present				-	10	NM_007300.3	c.2311T>C	synonymous	-0.83				BRCA1 C Terminus (BRCT) domain,Zinc finger	rs16940		0.302 (ref)	0.3237	0.1877	0.2776	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		untested	0.00001	6573.64	A=1198, G=802		A=616/582, G=403/399	2	
chr17:41245466	G/A	G	SNV		BRCA1	exonic	1								34.90	p.(=)		2000	G=0.651, A=0.349		Present				-	10	NM_007300.3	c.2082C>T	synonymous	-0.08				BRCA1 C Terminus (BRCT) domain,Zinc finger	rs1799949		0.324 (ref)	0.3244	0.2396	0.2957	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		untested	0.00001	5230.16	G=1302, A=698		G=700/602, A=393/305	1	
chr17:41245471	C/T	C	SNV		BRCA1	exonic	1								34.08	p.Asp693Asn		1998	C=0.6592, T=0.3408		Present				-	10	NM_007300.3	c.2077G>A	missense	0.13	0.05	23.0	0.001	BRCA1 C Terminus (BRCT) domain,Zinc finger	rs4986850		0.039	0.0702	0.0232	0.0543	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		non-pathogenic	0.00001	5018.9	C=1317, T=681		C=698/619, T=378/303	1	
chr17:56435885	G/T	G	SNV		RNF43	exonic	1								26.56	p.Leu418Met		1551	G=0.7344, T=0.2656		Present				-	9	NM_017763.4	c.1252C>A	missense	2.18	0.0	15.0	0.948	Zinc finger	rs2526374		0.398 (ref)	0.3591	0.4024	0.3738	YES	endoplasmic reticulum,endoplasmic reticulum membrane,integral to membrane,ligase activity,membrane,metal ion binding,nuclear envelope,nucleus,protein binding,zinc ion binding			0.00001	2554.74	G=1139, T=412		G=588/551, T=211/201	1	
chr17:56492800	C/C	T	SNV		RNF43	exonic	1								100.00	p.Ile47Val		1834	T=0.0, C=1.0		Present				-	2	NM_017763.4	c.139A>G	missense	0.97	0.1	29.0	0.001	Zinc finger	rs3744093		0.392 (ref)	0.3851	0.2174	0.3283	YES	endoplasmic reticulum,endoplasmic reticulum membrane,integral to membrane,ligase activity,membrane,metal ion binding,nuclear envelope,nucleus,protein binding,zinc ion binding			0.00001	27895.2	T=0, C=1834		T=0/0, C=946/888	1	
chr19:15271771	A/A	G	SNV		NOTCH3	exonic	1								100.00	p.Ala2223Val		1989	G=0.0, A=1.0		Present				-	33	NM_000435.2	c.6668C>T	missense	0.08	0.18	64.0	0.001	Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1044009		0.368 (ref)	0.1987	0.397	0.2651	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	30216.0	G=0, A=1989		G=0/0, A=904/1085	1	
chr19:15278057	G/G	A	SNV		NOTCH3	splicesite_3	1								100.00			1995	A=0.0, G=1.0		Present				-	29	NM_000435.2			0.62				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1548555		0.133 (ref)	0.1034	0.0236	0.0763	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	30341.7	A=0, G=1995		A=0/0, G=968/1027	2	
chr19:15285052	C/C	T	SNV		NOTCH3	exonic	1								100.00	p.(=)		1623	T=0.0, C=1.0		Present				-	25	NM_000435.2	c.4563A>G	synonymous	-1.43				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1044006		0.133 (ref)	0.1002	0.0223	0.0739	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	24670.8	T=0, C=1623		T=0/0, C=728/895	1	
chr19:15292437	C/C	T	SNV		NOTCH3	exonic	1								100.00	p.(=)		1169	T=0.0, C=1.0		Present				-	17	NM_000435.2	c.2742A>G	synonymous	-4.38				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1043997		0.233 (ref)	0.1299	0.3636	0.2095	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	17684.9	T=0, C=1169		T=0/0, C=638/531	1	
chr19:15295134	A/A	G	SNV		NOTCH3	exonic	1								100.00	p.(=)		1586	G=0.0, A=1.0		Present				-	16	NM_000435.2	c.2538C>T	synonymous	-0.59				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1043996		0.462 (ref)	0.2849	0.2762	0.4336	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	24008.1	G=0, A=1586		G=0/0, A=773/813	1	
chr19:15302844	C/C	T	SNV		NOTCH3	exonic	1								100.00	p.(=)		1995	T=0.0, C=1.0		Present				-	4	NM_000435.2	c.606A>G	synonymous	-2.59				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1043994		0.144 (ref)	0.1224	0.0878	0.1107	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	30308.1	T=0, C=1995		T=0/0, C=885/1110	1	
chr19:30314666	T/T	C	SNV		CCNE1	exonic	1								100.00	p.(=)		1986	C=0.0, T=1.0		Present				+	12	NM_001238.2	c.1215C>T	synonymous	-1.18				Cyclin	rs7257694		0.216 (ref)	0.3899	0.111	0.2954	YES	DNA-dependent DNA replication initiation,G1/S transition of mitotic cell cycle,Wnt receptor signaling pathway,androgen receptor binding,androgen receptor signaling pathway,antral ovarian follicle growth,cell division,cellular response to nutrient,centrosome,cyclin-dependent protein kinase holoenzyme complex,cyclin-dependent protein kinase regulator activity,cytoplasm,cytosol,kinase activity,liver development,mitotic cell cycle,nucleolus,nucleoplasm,nucleus,organ regeneration,positive regulation of cell differentiation,positive regulation of transcription, DNA-dependent,protein binding,protein kinase binding,protein phosphorylation,regulation of cyclin-dependent protein kinase activity,regulation of transcription involved in G1/S phase of mitotic cell cycle,response to corticosterone stimulus,response to cytokine stimulus,response to drug,response to estradiol stimulus,response to ethanol,response to methylmercury,response to organic nitrogen,response to progesterone stimulus,response to purine-containing compound,response to vitamin E,transcription coactivator activity			0.00001	30029.0	C=0, T=1986		C=0/0, T=1141/845	1	
chr20:36030939	C/C	G	SNV		SRC	exonic	1								100.00	p.(=)		1912	G=0.0, C=1.0		Present				+	12	NM_198291.2	c.1218G>C	synonymous	-2.02				Protein kinase domain,Protein tyrosine kinase,SH2 domain,SH3 domain,Variant SH3 domain	rs1885257		0.012 (ref)					ATP binding,Ras protein signal transduction,SH2 domain binding,SH3/SH2 adaptor activity,T cell costimulation,axon guidance,blood coagulation,bone resorption,branching involved in mammary gland duct morphogenesis,caveola,cell adhesion,cell cycle,cell junction assembly,cellular membrane organization,cytoplasm,cytoskeleton,cytosol,ephrin receptor binding,epidermal growth factor receptor signaling pathway,fibroblast growth factor receptor signaling pathway,forebrain development,heme binding,integrin binding,interspecies interaction between organisms,intracellular protein kinase cascade,ion channel binding,kinase activity,leukocyte migration,mitochondrial inner membrane,mitochondrion,nerve growth factor receptor signaling pathway,non-membrane spanning protein tyrosine kinase activity,nucleotide binding,nucleus,oogenesis,peptidyl-tyrosine phosphorylation,phosphorylation,plasma membrane,platelet activation,positive regulation of integrin activation,protein binding,protein kinase activity,protein phosphorylation,protein tyrosine kinase activity,receptor binding,regulation of bone resorption,regulation of intracellular estrogen receptor signaling pathway,regulation of vascular permeability,response to interleukin-1,signal complex assembly,signal transduction,uterus development	(2E)-N-{4-(3-bromophenyl)aminoquinazolin-6-yl}-4-(dimethylamino)but-2-enamide,1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo3,4-dpyrimidin-4-amine,1-1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl-3-naphthalen-1-ylurea,1-1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl-3-phenylurea,1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo3,4-DPyrimidin-4-Ylamine,1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo3,4-dpyrimidin-4-amine,1-cyclopentyl-3-(1H-pyrrolo2,3-bpyridin-5-yl)-1H-pyrazolo3,4-dpyrimidin-4-amine,2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE,3-4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO3,4-DPYRIMIDIN-3-YLPHENOL,4-(4-METHYL-1-PIPERAZINYL)METHYL-N-3-4-(3-PYRIDINYL)-2-PYRIMIDINYLAMINOPHENYL-BENZAMIDE,4-({4-(5-cyclopropyl-1H-pyrazol-3-yl)aminoquinazolin-2-yl}amino)phenylacetonitrile,Citric Acid,DPI59,Dasatinib,ISO24,Malonic acid,N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE,N-4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL-ACRYLAMIDE,N6-Benzyl Adenosine-5'-Diphosphate,Oxalic Acid,PAS219,PASBN,Phenylphosphate,Phosphonotyrosine,Purvalanol A,RU78191,RU78262,RU78299,RU78300,RU78783,RU79072,RU79073,RU79256,RU81843,RU82129,RU82197,RU82209,RU83876,RU84687,RU85053,RU85493,RU90395		0.00001	28805.8	G=0, C=1912		G=0/0, C=983/929	2	
chrX:66766604		G	GENE_EXPRESSION		AR								AR.E1E2				37				Present			4.2173e-11																						0.0					
chrX:66942826		T	GENE_EXPRESSION		AR								AR.E7E8				16274				Present			1.8549e-08																						0.0					
